<html xmlns="http://www.w3.org/1999/xhtml"> <head> <style type="text/css">
      	     		 
      	    a                          {background : #ffffff; }
      	    article                    {border-style : dotted; border-width : 2px; }
		 	
		 	div                        {background : #ffffcc;}
		 	div.abstract-title         {font-weight : bold ; font-size : 16pt;}
		 	div.ack                    {border-style : solid ; border-color : red; margin : 2em; }
		 	div.article-meta           {border-style : solid; border-width : 1 pt; margin 1em;}
		 	div.boxed-text             {margin : 5em; border-style : solid;}
		 	div.contrib-group          {margin : 1em; }
		 	div.fig                    {border-style : solid; border-width : 2px; margin : 2em; }
		 	div.funding                {font-weight : bold ; font-size : 16pt;}
		 	div.given-names            {font-style : italic;}
		 	div.intro                  {border-style : inset; margin : 5px;}
		 	div.introduction           {border-style : inset; margin : 5px;}
		 	div.journal-meta           {border-style : solid; border-width : 1 pt; margin 1em;}
		 	div.journal-title-group    {background : #ffeeee;}
		 	div.article-title          {font-weight : bold ; font-size : 18pt;}
		 	div.kwd                    {font-style : italic}
		 	div.meta-name              {font-weight : bold ; font-size : 16pt;}
		 	div.name                   {font-weight : bold;}
		 	div.alt-title              {font-style : italic; font-size : 12px;}
		 	
		 	div.sec                    {border : 2px; margin 5px; padding 2px;}
		 	div.title                  {font-family : courier; font-weight : bold;
		 	                            font-size : 16pt; margin : 5px;}
		 	
		 	div.materials_methods      {border-style : double; margin : 5px; }
		 	div.methods                {border-style : double; margin : 5px; }
		 	
		 	div.results                {border-style : solid; margin : 5px;}
		 	div.background             {border-style : dotted; margin : 5px;}
		 	
		 	div.discussion             {border-style : groove; margin : 5px;}
		 	div.conclusion             {border-style : ridge; margin : 5px;}
		 	div.conclusions             {border-style : ridge; margin : 5px;}
		 	div.supplementary-material {border-style : inset; margin : 5px;}
		 	div.abbreviations          {border-style : double; border-color : red; margin : 5px;}
		 	div.competinginterests     {border-style : double; border-color : blue; margin : 5px;}
		 	div.acknowledgements       {border-style : double; border-color : green; margin : 5px;}
		 	div.authors_contributions   {border-style : double; border-color : purple; margin : 5px;}
		 	
		 	div.publisher              {border-style : outset; margin : 5px;}
		 	div.fn-type-conflict       {background : #f88; }
		 	div.fn-type-con            {background : #ddf; }
		 	div.fn-type-other          {background : #ddd; }
		 	
		 	div.unknown                {background : #ffd;
									 	  border-style : solid;
									 	  border-width : 1px;
									 	  padding : 2 px;}
		 	  
      	    table                      {background : #ffffdd;}
		 	tr                         {background : #ddddff; padding : 1px;}
		 	
		 	span                       {background : #ffcccc;}
		 	
		 	span.citation-author       {font-family : helvetica; background : #ffeeee;}
		 	span.collab                {background : #ddffff; }
		 	span.comment               {font-family : courier; font-size : 6px; background : #ffaaff;}
		 	span.contrib               {background : #ffffff;}
		 	span.corresp               {background : #ddffdd; }
		 	span.doi                   {background : #ffffff;}
		 	span.email                 {font-family : courier; }
		 	span.etal                  {font-style : italic;}
		 	span.fpage                 {font-family : courier;}
		 	span.given-names           {background : #ffffff;}
		 	span.iso-abbrev            {background : #ffffff;}
		 	span.issn-epub             {background : #ffffff;}
		 	span.issn-ppub             {background : #ffffff;}
		 	span.journal-title         {background : #ffffff;}
		 	span.lpage                 {font-family : courier;}
		 	span.mixed-article-title   {font-style : italic ;}
		 	span.nlm-ta                {background : #ffffff;}
		 	span.pmc                   {background : #ffffff;}
		 	span.pmcid                 {background : #ffffff;}
		 	span.pmid                  {background : #ffffff;}
		 	span.publisher             {background : #ffffff;}
		 	span.publisher-id          {background : #ffffff;}
		 	span.publisher-name        {background : #ffffff;}
		 	span.source                {background : #ffffff;}
		 	span.subject               {background : #ffffff;}
		 	span.surname               {background : #ffffff;}
		 	span.volume                {font-family : courier; font-weight : bold;}
		 	span.year                  {font-family : courier ; font-style : italic;}
			</style> </head> <body> <div class="front" title="front"> <div class="journal-meta" tagx="journal-meta" title="journal-meta"><span class="nlm-ta" title="nlm-ta">J Enzyme Inhib Med Chem</span><span class="iso-abbrev" title="iso-abbrev">J Enzyme Inhib Med Chem</span><div class="journal-title-group" tagx="journal-title-group" title="journal-title-group"><span class="journal-title" tagx="journal-title" title="journal-title">Journal of Enzyme Inhibition and Medicinal Chemistry</span></div><span class="issn-ppub" tagx="issn" title="issn-ppub">1475-6366</span><span class="issn-epub" tagx="issn" title="issn-epub">1475-6374</span><div class="publisher" tagx="publisher" title="publisher"><span class="publisher-name" tagx="publisher-name" title="publisher-name">Taylor &amp;amp; Francis</span></div> </div> <div class="article-meta" tagx="article-meta" title="article-meta"><span class="pmcid" title="pmcid"> pmcid: <a href="http://www.ncbi.nlm.nih.gov/pubmed/7801072">7801072</a></span><span class="pmid" title="pmid"> pmid: <a href="http://www.ncbi.nlm.nih.gov/pubmed/33404277">33404277</a></span><span class="doi" title="doi"> doi: <a href="https://dx.doi.org/10.1080/14756366.2020.1850713">10.1080/14756366.2020.1850713</a></span><span class="publisher-id" title="publisher-id">1850713</span><div class="unknown" title="article-version" tag="article-version">
Version of Record</div> <div class="article-categories" title="article-categories">
: <span class="subject" title="subject">Research Article</span>: <span class="subject" title="subject">Research Paper</span></div> <div class="title-group" tagx="title-group" title="title-group"> <div class="article-title" title="article-title">
Design, synthesis and evaluation of carbazole derivatives as potential antimicrobial agents</div> <div class="alt-title" title="alt-title">
Y.-J. Xue et al.</div> </div> <div class="contrib-group" title="contrib-group"><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Xue</span><span class="given-names" tagx="given-names" title="given-names">Yi-Jie</span></span><a href="#AF0001" /><a href="#AF0002" /></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Li</span><span class="given-names" tagx="given-names" title="given-names">Ming-Yue</span></span><a href="#AF0001" /></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Jin</span><span class="given-names" tagx="given-names" title="given-names">Xue-Jun</span></span><a href="#AF0001" /></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zheng</span><span class="given-names" tagx="given-names" title="given-names">Chang-Ji</span></span><a href="#AF0001" /></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Piao</span><span class="given-names" tagx="given-names" title="given-names">Hu-Ri</span></span><a href="#AF0001" /><a href="#AN0001" /></span><span class="citation_author_institution" id="AF0001">[a], <span class="institution" title="institution">Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Yanbian University</span><span class="city" tagx="city" title="city">Yanji</span><span class="country" tagx="country" title="country">China</span></span><span class="citation_author_institution" id="AF0002">[b], <span class="institution" title="institution">School of Pharmacy, Fudan University</span><span class="city" tagx="city" title="city">Shanghai</span><span class="country" tagx="country" title="country">China</span></span></div> <div class="author-notes" title="author-notes"> <div class="corresp" title="corresp">
CONTACT Hu-Ri Piao <span class="email" tagx="email" title="email">piaohr@ybu.edu.cn</span><span class="institution" title="institution">Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Yanbian University College of Pharmacy</span>, <span class="city" tagx="city" title="city">Yanji</span><span class="postal-code" tagx="postal-code" title="postal-code">133002</span>, <span class="country" tagx="country" title="country">China</span></div> </div><span class="pub-date-" title="pub-date-">: <span>2021-1-1</span></span><span class="pub-date-" title="pub-date-">: <span>2021</span></span><span class="volume" tagx="volume" title="volume">36</span><span class="issue" tagx="issue" title="issue">1</span><span class="fpage" tagx="fpage" title="fpage">295</span><span class="lpage" tagx="lpage" title="lpage">306</span><div class="permissions"><span class="copyright" title="copyright">(C) <span class="copyright-holder" tagx="copyright-holder" title="copyright-holder">The Author(s)</span>, <span class="copyright-year" tagx="copyright-year" title="copyright-year">2020</span></span><span class="license" title="license"><span class="license-p" title="license-p">This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<a href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</a>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</span></span></div><a class="self-uri" href="IENZ_36_1850713.pdf" title="self-uri">IENZ_36_1850713.pdf</a><div class="abstract" title="abstract"> <div class="abstract-title" title="abstract-title">
Abstract</div> <div class="title" tagx="title" title="title">
Abstract</div> <p>Five series of novel carbazole derivatives containing an aminoguanidine, dihydrotriazine, thiosemicarbazide, semicarbazide or isonicotinic moiety were designed, synthesised and evaluated for their antimicrobial activities. Most of the compounds exhibited potent inhibitory activities towards different bacterial strains (including one multidrug-resistant clinical isolate) and one fungal strain with minimum inhibitory concentrations (MICs) between 0.5 and 16â€‰Âµg/ml. Compounds <b>8f</b> and <b>9d</b> showed the most potent inhibitory activities (MICs of 0.5â€"2â€‰Âµg/ml). Furthermore, compounds <b>8b</b>, <b>8d</b>, <b>8f</b>, <b>8k</b>, <b>9b</b> and <b>9e</b> with antimicrobial activities were not cytotoxic to human gastric cancer cell lines (SGC-7901 and AGS) or a normal human liver cell line (L-02). Structureâ€"activity relationship analyses and docking studies implicated the dihydrotriazine group in increasing the antimicrobial potency and reducing the toxicity of the carbazole compounds. <i>In vitro</i> enzyme activity assays suggested that compound <b>8f</b> binding to dihydrofolate reductase might account for the antimicrobial effect.</p> </div> <div class="kwd-group"> <div class="title" tagx="title" title="title">
Keywords</div> <div class="kwd" title="kwd">
Carbazole</div> <div class="kwd" title="kwd">
antibacterial activities</div> <div class="kwd" title="kwd">
antifungal activities</div> <div class="kwd" title="kwd">
structureâ€"activity relationship</div> <div class="kwd" title="kwd">
cytotoxicity</div> </div> <div class="counts" title="counts"><span class="fig-count" title="fig-count">fig-count: </span><span class="table-count" title="table-count">table-count: </span><span class="page-count" title="page-count">page-count: </span><span class="word-count" title="word-count">word-count: </span></div> </div> </div> <div class="body" title="body"> <div class="introduction" title="sec"><span class="label" tagx="label" title="label">1.</span><div class="title" tagx="title" title="title">
Introduction</div> <p>The steady increase of microbial pathogens that do not respond to conventional treatments presents a significant threat to global public health. Fungal and bacterial infections are becoming progressively more resistant towards currently available antimicrobial medicines, such as antibiotics. Therefore, there is an urgent requirement for new drugs that target these pathogens. Without effective antimicrobials for prevention and treatment of infections, medical procedures such as organ transplantation, chemotherapy, diabetes management and routine surgery (e.g. caesarean sections or hip replacements) have a significantly higher risk of morbidity and mortality<a href="#CIT0001"><sup>1</sup></a>. The scale of the threat of antimicrobial resistance has led to the development of numerous strategies to conserve and make more effective use of existing antibiotics and to promote the development of novel antimicrobials<a href="#CIT0002"><sup>2</sup></a>. In 2010, the Infectious Diseases Society of America (IDSA) launched the 10â€‰Ã—â€‰20 initiative that called for the development of 10 novel, safe and effective systemic antibiotics by 2020<a href="#CIT0003"><sup>3</sup></a>.</p> <p>Carbazole alkaloids have attracted considerable attention in medicinal chemistry because they exhibit a broad spectrum of biological and pharmacological activities, including antibacterial, antituberculous, antitumour, antioxidant and anti-inflammatory properties<a href="#CIT0004"><sup>4â€"13</sup></a>. In our previous studies, guanidines exhibited significant antibacterial activity and triazine ring-containing compounds displayed hypoglycaemic, antitumour and antibacterial activities<a href="#CIT0014"><sup>14</sup></a><sup>,</sup><a href="#CIT0015"><sup>15</sup></a>. Dihydrotriazine compounds have a higher hydrophobicity compared with guanidine compounds and several molecules containing this scaffold have been reported as antibacterial agents<a href="#CIT0016"><sup>16â€"18</sup></a>. Recent studies have identified dihydrotriazine-containing compounds as inhibitors of dihydrofolate reductase (DHFR), a ubiquitous enzyme that catalyses the conversion of 7,8-dihydrofolate to 5,6,7,8-tetrahydrofolate, which is involved in metabolic reactions such as purine and thymidine nucleotide biosynthesis<a href="#CIT0019"><sup>19</sup></a><sup>,</sup><a href="#CIT0020"><sup>20</sup></a>. DHFR is required by all organisms to grow and multiply; however, selective inhibitors of microbial enzymes have been utilised as therapeutic agents.</p> <p>Here, we report the design and synthesis of five series of novel carbazole derivatives (<a href="#F0001">Figure 1</a>), totaling 30 compounds and the subsequent <i>inÂ vitro</i> evaluations of their antibacterial and antifungal activities. Several different substituents were systematically introduced onto the carbazole ring and their effects on the overall antimicrobial activity were investigated.</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 1.</span></a></div>   <p>The structures of the target compounds.</p>   </div> </div> <div class="experimental" title="sec"><span class="label" tagx="label" title="label">2.</span><div class="title" tagx="title" title="title">
Experimental</div> <div class="chemistry" title="sec"><span class="label" tagx="label" title="label">2.1.</span><div class="title" tagx="title" title="title">
Chemistry</div> <p>All reagents were obtained commercially and were used without further purification. Solvents were dried according to standard procedures. Reactions were monitored by thin-layer chromatography (TLC) on silica gel plates. Melting points were determined in open capillary tubes and were uncorrected. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were measured on an AV-300 (Bruker, Switzerland), and all chemical shifts were given in ppm relative to TMS. Mass spectra were measured on a HP1100LC (Agilent Technologies). High-resolution mass spectra were measured on an MALDI-TOF/TOF mass spectrometer (Bruker Daltonik, Germany).</p> <div class="proceduretosynthesisecompound2a" title="sec"><span class="label" tagx="label" title="label">2.1.1.</span><div class="title" tagx="title" title="title">
Procedure to synthesise compound 2a</div> <p>To a solution of carbazole (1.03â€‰g, 6.16â€‰mmol) in DMC (10â€‰ml), DABCO (0.069â€‰g, 0.62â€‰mmol) was added and the resulting solution was heated to 90â€"95â€‰Â°C for 24â€‰h to give compound <b>2a</b><a href="#CIT0021"><sup>21</sup></a>.</p> </div> <div class="proceduretosynthesisecompound2â€‰b" title="sec"><span class="label" tagx="label" title="label">2.1.2.</span><div class="title" tagx="title" title="title">
Procedure to synthesise compound 2â€‰b</div> <p>A solution of potassium hydroxide (1.21â€‰g, 21.56â€‰mmol) and bromoethane (1.01â€‰g, 9.24â€‰mmol) in acetone (20â€‰ml) was added to carbazole (1.03â€‰g, 6.16â€‰mmol) and the mixture was stirred at room temperature for 2â€‰h to give compound <b>2b</b><a href="#CIT0022"><sup>22</sup></a>.</p> </div> <div class="generalproceduretosynthesisecompounds2câ€" title="sec"><span class="label" tagx="label" title="label">2.1.3.</span><div class="title" tagx="title" title="title">
General procedure to synthesise compounds 2câ€"k</div> <p>To a solution of carbazole (1.67â€‰g, 9.00â€‰mmol) in DMF (20â€‰ml) followed by addition of NaH (400â€‰mg, 16.50â€‰mmol) in small portions at 0â€‰Â°C, over 5â€‰min, benzyl halide (9.90â€‰mmol) was added drop wise at 0â€‰Â°C, over 5â€‰min, the mixture was stirred at room temperature for 8â€"18â€‰h to give compounds <b>2câ€"k</b><a href="#CIT0023"><sup>23</sup></a>.</p> </div> <div class="generalproceduretosynthesisecompounds4aâ€" title="sec"><span class="label" tagx="label" title="label">2.1.4.</span><div class="title" tagx="title" title="title">
General procedure to synthesise compounds 4aâ€"l</div> <p>In a three-necked round-bottomed flask, POCl<sub>3</sub> (700â€‰mg, 4.56â€‰mmol) was added dropwise to DMF (400â€‰mg, 5.42â€‰mmol) while stirring at 0â€‰Â°C. The mixture was then stirred at room temperature for 1â€‰h. A solution of 9-substituted carbazole (1.93â€‰mmol) was slowly added to this mixture over 5â€‰min at 45â€‰Â°C, and then the temperature was raised to 95â€‰Â°C for 8â€"18â€‰h to yield compounds <b>4a</b>â€"<b>l</b><a href="#CIT0023"><sup>23</sup></a>.</p> </div> <div class="generalproceduretosynthesisecompounds8aâ€" title="sec"><span class="label" tagx="label" title="label">2.1.5.</span><div class="title" tagx="title" title="title">
General procedure to synthesise compounds 8aâ€"l</div> <p>A mixture of the required compound <b>4</b> (2â€‰mmol) and metformin hydrochloride (2â€‰mmol) in glacial acetic acid (20â€‰ml) was heated under reflux at 120â€‰Â°C for 4â€"8â€‰h (completion of the reaction was monitored by TLC). The solvent was then removed under reduced pressure. The crude products were purified by silica gel column chromatography using dichloromethane:methanol (20:1) as the eluent.</p> <div class="n2,n2-dimethyl-6-(9-methyl-9h-carbazol-3-yl)-3,6-dihydro-1,3,5-triazine-2,4-diamine(8a)" title="sec"><span class="label" tagx="label" title="label">2.1.5.1.</span><div class="title" tagx="title" title="title">
N<sup>2</sup>,N<sup>2</sup>-Dimethyl-6-(9-methyl-9H-carbazol-3-yl)-3,6-dihydro-1,3,5-triazine-2,4-diamine (8a)</div> <p>White powder; yield 52.3%; m.p. 267.3â€"268.9â€‰Â°C. IR (KBr) cm<sup>âˆ’1</sup>: 3300, 3134 (NH<sub>2</sub>, NH), 1606 (Câ€‰=â€‰N). <sup>1</sup>H NMR (300â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 8.88 (br s, 2H, NH<sub>2</sub>), 8.26â€"8.11 (m, 2H, Ar-H and NH), 7.76â€"7.46 (m, 5H, Ar-H), 7.25 (t, 1H, <i>J</i>â€‰=â€‰7.6â€‰Hz, Ar-H), 5.99 (s, 1H, CH), 3.90 (s, 3H, CH<sub>3</sub>), 3.08 (s, 6H, CH<sub>3</sub>). <sup>13â€‰</sup>C NMR (75â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 157.59, 155.85, 141.05, 140.75, 131.06, 126.01, 123.96, 121.75, 121.63, 120.13, 119.01, 118.02, 109.39 (2â€‰C), 62.77, 36.93 (2â€‰C), 29.12. HRMS (MALDI) calcd for C<sub>18</sub>H<sub>20</sub>N<sub>6</sub> [Mâ€‰+â€‰H]<sup>+</sup>: 321.1822, found: 321.1806.</p> </div> <div class="6-(9-ethyl-9h-carbazol-3-yl)-n2,n2-dimethyl-3,6-dihydro-1,3,5-triazine-2,4-diamine(8â€‰b)" title="sec"><span class="label" tagx="label" title="label">2.1.5.2.</span><div class="title" tagx="title" title="title">
6-(9-Ethyl-9H-carbazol-3-yl)-N<sup>2</sup>,N<sup>2</sup>-dimethyl-3,6-dihydro-1,3,5-triazine-2,4-diamine (8â€‰b)</div> <p>White powder; yield 61.6%; m.p. 256.9â€"259.8â€‰Â°C. IR (KBr) cm<sup>âˆ’1</sup>: 3356, 3132 (NH<sub>2</sub>, NH), 1598 (Câ€‰=â€‰N). <sup>1</sup>H NMR (300â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 8.80 (br s, 2H, NH<sub>2</sub>), 8.25â€"8.12 (m, 2H, Ar-H), 7.68 (dd, 2H, <i>J</i>â€‰=â€‰15.0, 8.4â€‰Hz, Ar-H), 7.51 (ddd, 2H, <i>J</i>â€‰=â€‰16.2, 8.3, 1.5â€‰Hz, Ar-H), 7.24 (t, 1H, <i>J</i>â€‰=â€‰7.4â€‰Hz, Ar-H), 5.98 (s, 1H, CH), 5.76 (s, 1H, NH), 4.48 (q, 2H, <i>J</i>â€‰=â€‰7.1â€‰Hz, CH<sub>2</sub>), 3.08 (s, 6H, CH<sub>3</sub>), 1.31 (t, 3H, <i>J</i>â€‰=â€‰7.0â€‰Hz, CH<sub>3</sub>). <sup>13â€‰</sup>C NMR (75â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 157.66, 155.83, 139.95, 139.66, 131.06, 126.02, 123.98, 121.95, 121.82, 120.27, 118.98, 118.21, 109.34 (2â€‰C), 62.76, 37.06, 36.94 (2â€‰C), 13.67. HRMS (MALDI) calcd for C<sub>19</sub>H<sub>22</sub>N<sub>6</sub> [Mâ€‰+â€‰H]<sup>+</sup>: 335.1979, found: 335.1967.</p> </div> <div class="6-(9-benzyl-9h-carbazol-3-yl)-n2,n2-dimethyl-3,6-dihydro-1,3,5-triazine-2,4-diamine(8c)" title="sec"><span class="label" tagx="label" title="label">2.1.5.3.</span><div class="title" tagx="title" title="title">
6-(9-Benzyl-9H-carbazol-3-yl)-N<sup>2</sup>,N<sup>2</sup>-dimethyl-3,6-dihydro-1,3,5-triazine-2,4-diamine (8c)</div> <p>White powder; yield 46.1%; m.p. 237.1â€"238.8â€‰Â°C. IR (KBr) cm<sup>âˆ’1</sup>: 3440, 3240 (NH<sub>2</sub>, NH), 1606 (Câ€‰=â€‰N). <sup>1</sup>H NMR (300â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 8.83 (br s, 2H, NH<sub>2</sub>), 8.27â€"8.16 (m, 2H, Ar-H), 7.70 (dd, 2H, <i>J</i>â€‰=â€‰11.5, 8.4â€‰Hz, Ar-H), 7.55â€"7.44 (m, 2H, Ar-H), 7.25 (dtd, 4H, <i>J</i>â€‰=â€‰8.1, 6.5, 4.4â€‰Hz, Ar-H), 7.16 (dd, 2H, <i>J</i>â€‰=â€‰8.0, 1.7â€‰Hz, Ar-H), 5.97 (s, 1H, CH), 5.76 (s, 1H, NH), 5.70 (s, 2H, CH<sub>2</sub>), 3.07 (s, 6H, CH<sub>3</sub>). <sup>13â€‰</sup>C NMR (75â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 157.62, 155.85, 140.60, 140.29, 137.65, 131.37, 128.59 (2â€‰C), 127.28 (2â€‰C), 126.71, 126.20, 124.18, 122.01, 121.92, 120.30, 119.35, 118.29, 109.84 (2â€‰C), 62.76, 45.67, 36.96, 33.9. HRMS (MALDI) calcd for C<sub>24</sub>H<sub>24</sub>N<sub>6</sub> [Mâ€‰+â€‰H]<sup>+</sup>: 397.2135, found: 397.2134.</p> </div> <div class="n2,n2-dimethyl-6-(9-(4-methylbenzyl)-9h-carbazol-3-yl)-3,6-dihydro-1,3,5-triazine-2,4-diamine(8d)" title="sec"><span class="label" tagx="label" title="label">2.5.1.4.</span><div class="title" tagx="title" title="title">
N<sup>2</sup>,N<sup>2</sup>-Dimethyl-6-(9-(4-methylbenzyl)-9H-carbazol-3-yl)-3,6-dihydro-1,3,5-triazine-2,4-diamine (8d)</div> <p>White powder; yield 58.8%; m.p. 237.2â€"239.8â€‰Â°C. IR (KBr) cm<sup>âˆ’1</sup>: 3350, 3037 (NH<sub>2</sub>, NH), 1609 (Câ€‰=â€‰N). <sup>1</sup>H NMR (300â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 8.88 (s, 1H, NH<sub>2</sub>), 8.82 (s, 1H, NH<sub>2</sub>), 8.32â€"8.14 (m, 2H, Ar-H), 7.69 (dd, 2H, <i>J</i>â€‰=â€‰12.8, 8.2â€‰Hz, Ar-H), 7.49 (dd, 2H, <i>J</i>â€‰=â€‰19.7, 8.4â€‰Hz, Ar-H), 7.25 (t, 1H, <i>J</i>â€‰=â€‰7.4â€‰Hz, Ar-H), 7.07 (d, 4H, <i>J</i>â€‰=â€‰4.7â€‰Hz, Ar-H), 5.97 (s, 1H, CH), 5.77 (s, 1H, NH), 5.65 (s, 2H, CH<sub>2</sub>), 3.07 (s, 6H, CH<sub>3</sub>), 2.22 (s, 3H, CH<sub>3</sub>). <sup>13â€‰</sup>C NMR (75â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 158.06, 156.35, 141.06, 140.77, 136.92, 135.05, 131.69, 129.58 (2â€‰C), 127.20 (2â€‰C), 126.63, 124.63, 122.47, 122.40, 120.75, 119.77, 118.79, 110.33 (2â€‰C), 63.34, 55.44, 45.95, 37.41, 21.09. HRMS (MALDI) calcd for C<sub>25</sub>H<sub>26</sub>N<sub>6</sub> [Mâ€‰+â€‰H]<sup>+</sup>: 411.2292, found: 411.2299.</p> </div> <div class="6-(9-(2-fluorobenzyl)-9h-carbazol-3-yl)-n2,n2-dimethyl-3,6-dihydro-1,3,5-triazine-2,4-diamine(8e)" title="sec"><span class="label" tagx="label" title="label">2.5.1.5.</span><div class="title" tagx="title" title="title">
6-(9-(2-Fluorobenzyl)-9H-carbazol-3-yl)-N<sup>2</sup>,N<sup>2</sup>-dimethyl-3,6-dihydro-1,3,5-triazine-2,4-diamine (8e)</div> <p>White powder; yield 40.1%; m.p. 201.2â€"205.0â€‰Â°C. IR (KBr) cm<sup>âˆ’1</sup>: 3423, 3144 (NH<sub>2</sub>, NH), 1603 (Câ€‰=â€‰N). <sup>1</sup>H NMR (300â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 8.90 (s, 1H, NH<sub>2</sub>), 8.84 (s, 1H, NH<sub>2</sub>), 8.30â€"8.16 (m, 2H, Ar-H), 7.68 (dd, 2H, <i>J</i>â€‰=â€‰13.2, 8.3â€‰Hz, Ar-H), 7.56â€"7.43 (m, 2H, Ar-H), 7.33â€"7.22 (m, 3H, Ar-H), 7.03 (td, 1H, <i>J</i>â€‰=â€‰7.4, 1.6â€‰Hz, Ar-H), 6.88â€"6.78 (m, 1H, Ar-H), 5.97 (s, 1H, CH), 5.77 (s, 3H, NH and CH<sub>2</sub>), 3.07 (s, 6H, CH<sub>3</sub>). <sup>13â€‰</sup>C NMR (75â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 161.69, 158.44, 157.61, 155.96, 140.57, 140.28, 131.43, 129.50 (d, 1â€‰C, <i>J</i>â€‰=â€‰8.1â€‰Hz), 128.71 (d, 1â€‰C, <i>J</i>â€‰=â€‰4.2â€‰Hz), 126.23, 124.57 (d, 1â€‰C, <i>J</i>â€‰=â€‰3.4â€‰Hz), 124.22, 124.04, 122.08 (d, 1â€‰C, <i>J</i>â€‰=â€‰2.3â€‰Hz), 120.28, 119.50, 118.34, 115.65, 115.37, 109.75, 62.92, 62.01, 56.01, 36.95. HRMS (MALDI) calcd for C<sub>24</sub>H<sub>23</sub>FN<sub>6</sub> [Mâ€‰+â€‰H]<sup>+</sup>: 415.2041, found: 415.2037.</p> </div> <div class="6-(9-(2,4-dichlorobenzyl)-9h-carbazol-3-yl)-n2,n2-dimethyl-3,6-dihydro-1,3,5-triazine-2,4-diamine(8f)" title="sec"><span class="label" tagx="label" title="label">2.5.1.6.</span><div class="title" tagx="title" title="title">
6-(9-(2,4-Dichlorobenzyl)-9H-carbazol-3-yl)-N<sup>2</sup>,N<sup>2</sup>-dimethyl-3,6-dihydro-1,3,5-triazine-2,4-diamine (8f)</div> <p>White powder; yield 40.1%; m.p. 255.2â€"257.1â€‰Â°C. IR (KBr) cm<sup>âˆ’1</sup>: 3240, 3060 (NH<sub>2</sub>, NH), 1603 (Câ€‰=â€‰N). <sup>1</sup>H NMR (300â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 8.93â€"8.72 (br s, 2H, NH<sub>2</sub>), 8.35â€"8.18 (m, 2H, Ar-H), 7.75 (d, 1H, <i>J</i>â€‰=â€‰2.1â€‰Hz, Ar-H), 7.68â€"7.17 (m, 7H, Ar-H), 6.33 (d, 1H, <i>J</i>â€‰=â€‰8.4â€‰Hz, CH), 5.97 (s, 1H, NH), 5.76 (s, 2H, CH<sub>2</sub>), 3.08 (s, 6H, CH<sub>3</sub>). <sup>13</sup>C NMR (75â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 157.55, 155.97, 140.52, 140.25, 133.76, 132.77, 132.69, 131.74, 129.10, 128.50, 127.69, 126.43, 124.41, 122.17, 120.43 (2â€‰C), 119.76, 118.48, 109.63 (2â€‰C), 62.92, 45.32, 43.47, 36.95. HRMS (MALDI) calcd for C<sub>24</sub>H<sub>22</sub>Cl<sub>2</sub>N<sub>6</sub> [Mâ€‰+â€‰H]<sup>+</sup>: 465.1356, found: 465.1359. Purity: 97.41% by HPLC (A: 0.1% FA in H<sub>2</sub>O; B: 0.1% FA in CH<sub>3</sub>CN, graded: 20â€"100%), t<sub>R</sub> 12.273â€‰min, Î»: 250â€‰nm.</p> </div> <div class="6-(9-(2-chlorobenzyl)-9h-carbazol-3-yl)-n2,n2-dimethyl-3,6-dihydro-1,3,5-triazine-2,4-diamine(8â€‰g)" title="sec"><span class="label" tagx="label" title="label">2.1.5.7.</span><div class="title" tagx="title" title="title">
6-(9-(2-Chlorobenzyl)-9H-carbazol-3-yl)-N<sup>2</sup>,N<sup>2</sup>-dimethyl-3,6-dihydro-1,3,5-triazine-2,4-diamine (8â€‰g)</div> <p>White powder; yield 37.6%; m.p. 240.7â€"243.2â€‰Â°C. IR (KBr) cm<sup>âˆ’1</sup>: 3396, 3211 (NH<sub>2</sub>, NH), 1603 (Câ€‰=â€‰N). <sup>1</sup>H NMR (300â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 8.86 (s, 1H, NH<sub>2</sub>), 8.81 (s, 1H, NH<sub>2</sub>), 8.38â€"8.20 (m, 2H, Ar-H), 7.70â€"7.39 (m, 6H, Ar-H), 7.37â€"7.23 (m, 2H, Ar-H), 7.11 (dd, 1H, <i>J</i>â€‰=â€‰8.8, 6.3â€‰Hz, Ar-H), 6.36 (d, 1H, <i>J</i>â€‰=â€‰8.0â€‰Hz, CH), 5.98 (s, 1H, NH), 5.84â€"5.75 (m, 2H, CH<sub>2</sub>), 3.09 (s, 6H, CH<sub>3</sub>). <sup>13â€‰</sup>C NMR (75â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 157.99, 156.37, 141.07, 140.80, 134.95, 132.24, 132.07, 130.10, 129.52, 127.97, 127.59, 126.86, 124.86, 122.57, 122.54, 120.90, 120.13, 118.95, 110.13 (2â€‰C), 63.36, 55.43, 44.22, 37.42. HRMS (MALDI) calcd for C<sub>24</sub>H<sub>23</sub>ClN<sub>6</sub> [Mâ€‰+â€‰H]<sup>+</sup>: 431.1745, found: 431.1733.</p> </div> <div class="6-(9-(3-chlorobenzyl)-9h-carbazol-3-yl)-n2,n2-dimethyl-3,6-dihydro-1,3,5-triazine-2,4-diamine(8â€‰h)" title="sec"><span class="label" tagx="label" title="label">2.1.5.8.</span><div class="title" tagx="title" title="title">
6-(9-(3-Chlorobenzyl)-9H-carbazol-3-yl)-N<sup>2</sup>,N<sup>2</sup>-dimethyl-3,6-dihydro-1,3,5-triazine-2,4-diamine (8â€‰h)</div> <p>White powder; yield 54.9%; m.p. 207.0â€"209.2â€‰Â°C. IR (KBr) cm<sup>âˆ’1</sup>: 3313, 3029 (NH<sub>2</sub>, NH), 1600 (Câ€‰=â€‰N). <sup>1</sup>H NMR (300â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 8.87 (s, 1H, NH<sub>2</sub>), 8.81 (s, 1H, NH<sub>2</sub>), 8.34â€"8.16 (m, 2H, Ar-H), 7.71 (dd, 2H, <i>J</i>â€‰=â€‰13.6, 8.3â€‰Hz, Ar-H), 7.59â€"7.45 (m, 2H, Ar-H), 7.39â€"7.20 (m, 4H, Ar-H), 7.06 (dd, 1H, <i>J</i>â€‰=â€‰6.3, 2.9â€‰Hz, Ar-H), 5.97 (s, 1H, CH), 5.77 (s, 1H, NH), 5.74 (s, 2H, CH<sub>2</sub>), 3.12 (s, 6H, CH<sub>3</sub>). <sup>13â€‰</sup>C NMR (75â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 158.06, 156.36, 140.96, 140.74, 140.69, 133.67, 131.94, 131.03, 127.78, 127.03, 126.80, 125.77, 124.82, 122.52, 122.46, 120.85, 120.02, 118.91, 110.23 (2â€‰C), 63.34, 55.44, 45.55, 37.42. HRMS (MALDI) calcd for C<sub>24</sub>H<sub>23</sub>ClN<sub>6</sub> [Mâ€‰+â€‰H]<sup>+</sup>: 431.1745, found: 431.1749.</p> </div> <div class="6-(9-(4-chlorobenzyl)-9h-carbazol-3-yl)-n2,n2-dimethyl-3,6-dihydro-1,3,5-triazine-2,4-diamine(8i)" title="sec"><span class="label" tagx="label" title="label">2.1.5.9.</span><div class="title" tagx="title" title="title">
6-(9-(4-Chlorobenzyl)-9H-carbazol-3-yl)-N<sup>2</sup>,N<sup>2</sup>-dimethyl-3,6-dihydro-1,3,5-triazine-2,4-diamine (8i)</div> <p>White powder; yield 36.7%; m.p. 262.4â€"264.1â€‰Â°C. IR (KBr) cm<sup>âˆ’1</sup>: 3373, 3059 (NH<sub>2</sub>, NH), 1603 (Câ€‰=â€‰N). <sup>1</sup>H NMR (300â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 9.00 (s, 1H, NH<sub>2</sub>), 8.94 (s, 1H, NH<sub>2</sub>), 8.36â€"8.14 (m, 2H, Ar-H), 7.69 (dd, 2H, <i>J</i>â€‰=â€‰14.6, 8.2â€‰Hz, Ar-H), 7.60â€"7.43 (m, 3H, Ar-H), 7.35 (dd, 2H, <i>J</i>â€‰=â€‰8.6, 2.1â€‰Hz, Ar-H), 7.29â€"7.13 (m, 3H, Ar-H and NH), 5.98 (s, 1H, CH), 5.72 (s, 2H, CH<sub>2</sub>), 3.07 (s, 6H, CH<sub>3</sub>). <sup>13â€‰</sup>C NMR (75â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 158.02, 156.35, 140.95, 140.67, 137.15, 132.36, 131.92, 129.05 (4â€‰C), 126.75, 124.73, 122.52, 122.46, 120.83, 119.96, 118.85, 110.26 (2â€‰C), 63.32, 49.04, 45.47, 37.41. HRMS (MALDI) calcd for C<sub>24</sub>H<sub>23</sub>ClN<sub>6</sub> [Mâ€‰+â€‰H]<sup>+</sup>: 431.1745, found: 431.1761.</p> </div> <div class="6-(9-(4-bromobenzyl)-9h-carbazol-3-yl)-n2,n2-dimethyl-3,6-dihydro-1,3,5-triazine-2,4-diamine(8j)" title="sec"><span class="label" tagx="label" title="label">2.1.5.10.</span><div class="title" tagx="title" title="title">
6-(9-(4-Bromobenzyl)-9H-carbazol-3-yl)-N<sup>2</sup>,N<sup>2</sup>-dimethyl-3,6-dihydro-1,3,5-triazine-2,4-diamine (8j)</div> <p>White powder; yield 35.1%; m.p. 248.7â€"252.1â€‰Â°C. IR (KBr) cm<sup>âˆ’1</sup>: 3311, 3054 (NH<sub>2</sub>, NH), 1603 (Câ€‰=â€‰N). <sup>1</sup>H NMR (300â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 9.06 (s, 1H, NH<sub>2</sub>), 8.99 (s, 1H, NH<sub>2</sub>), 8.34â€"8.13 (m, 2H, Ar-H), 7.68 (dd, 2H, <i>J</i>â€‰=â€‰15.2, 8.3â€‰Hz, Ar-H), 7.63â€"7.41 (m, 5H, Ar-H), 7.25 (t, 1H, <i>J</i>â€‰=â€‰7.5â€‰Hz, Ar-H), 7.17â€"7.06 (m, 2H, Ar-H and NH), 5.99 (s, 1H, CH), 5.69 (s, 2H, CH<sub>2</sub>), 3.07 (s, 6H, CH<sub>3</sub>). <sup>13â€‰</sup>C NMR (75â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 157.53, 155.87, 140.47, 140.20, 137.10, 131.49(4â€‰C), 128.91 (2â€‰C), 126.28, 124.27, 122.04, 121.98, 120.37, 119.49, 118.39, 109.79 (2â€‰C), 62.86, 45.04, 36.94 (2â€‰C). HRMS (MALDI) calcd for C<sub>24</sub>H<sub>23</sub>BrN<sub>6</sub> [Mâ€‰+â€‰H]<sup>+</sup>: 475.1240, found: 475.1230.</p> </div> <div class="4-((3-(4-amino-6-(dimethylamino)-2,5-dihydro-1,3,5-triazin-2-yl)-9h-carbazol-9-yl)methyl)benzonitrile(8k)" title="sec"><span class="label" tagx="label" title="label">2.1.5.11.</span><div class="title" tagx="title" title="title">
4-((3-(4-Amino-6-(dimethylamino)-2,5-dihydro-1,3,5-triazin-2-yl)-9H-carbazol-9-yl)methyl)benzonitrile (8k)</div> <p>White powder; yield 52.9%; m.p. 234.1â€"235.4â€‰Â°C. IR (KBr) cm<sup>âˆ’1</sup>: 3306, 3061 (NH<sub>2</sub>, NH), 1605 (Câ€‰=â€‰N). <sup>1</sup>H NMR (300â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 9.06 (s, 1H, NH<sub>2</sub>), 9.01 (s, 1H, NH<sub>2</sub>), 8.35â€"8.15 (m, 2H, Ar-H), 7.78â€"7.62 (m, 4H, Ar-H), 7.56 (d, 1H, <i>J</i>â€‰=â€‰8.4â€‰Hz, Ar-H), 7.51â€"7.43 (m, 1H, Ar-H), 7.36â€"7.23 (m, 3H, Ar-H), 6.01 (s, 1H, CH), 5.83 (s, 2H, CH<sub>2</sub>), 5.77 (s, 1H, NH), 3.09 (s, 6H, CH<sub>3</sub>). <sup>13â€‰</sup>C NMR (75â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 158.06, 156.33, 143.92, 140.95, 140.66, 133.04 (2â€‰C), 132.15, 127.98 (2â€‰C), 126.82, 124.80, 122.58, 122.54, 120.87, 120.10, 119.11, 118.88, 110.59, 110.18 (2â€‰C), 63.28, 55.41, 49.03, 37.42. HRMS (MALDI) calcd for C<sub>25</sub>H<sub>23</sub>N<sub>7</sub> [Mâ€‰+â€‰H]<sup>+</sup>: 422.2088, found: 422.2077.</p> </div> <div class="6-(6-bromo-9-phenyl-9h-carbazol-3-yl)-n2,n2-dimethyl-3,6-dihydro-1,3,5-triazine-2,4-diamine(8â€‰l)" title="sec"><span class="label" tagx="label" title="label">2.1.5.12.</span><div class="title" tagx="title" title="title">
6-(6-Bromo-9-phenyl-9H-carbazol-3-yl)-N<sup>2</sup>,N<sup>2</sup>-dimethyl-3,6-dihydro-1,3,5-triazine-2,4-diamine (8â€‰l)</div> <p>White powder; yield 41.4%; m.p. 221.5â€"224.8â€‰Â°C. IR (KBr) cm<sup>âˆ’1</sup>: 3383, 3070 (NH<sub>2</sub>, NH), 1600 (Câ€‰=â€‰N). <sup>1</sup>H NMR (300â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 9.19 (s, 2H, NH<sub>2</sub>), 8.44 (d, 2H, <i>J</i>â€‰=â€‰19.4â€‰Hz, Ar-H), 7.64 (dd, 4H, <i>J</i>â€‰=â€‰15.7, 8.1â€‰Hz, Ar-H), 7.55 (d, 3H, <i>J</i>â€‰=â€‰7.6â€‰Hz, Ar-H), 7.39 (d, 1H, <i>J</i>â€‰=â€‰8.4â€‰Hz, Ar-H), 7.29 (t, 1H, <i>J</i>â€‰=â€‰6.9â€‰Hz, Ar-H), 6.05 (s, 1H, CH), 5.76 (s, 1H, NH), 3.08 (s, 6H, CH<sub>3</sub>). <sup>13â€‰</sup>C NMR (75â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 158.01, 156.25, 141.08, 139.79, 136.62, 133.51, 130.71 (2â€‰C), 129.41, 128.52, 127.02 (2â€‰C), 125.85, 124.88, 123.47, 121.88, 119.35, 112.82, 112.18, 110.60, 63.04, 55.41, 49.03. HRMS (MALDI) calcd for C<sub>23</sub>H<sub>21</sub>BrN<sub>6</sub> [Mâ€‰+â€‰H]<sup>+</sup>: 461.1084, found: 461.1066. Purity: 98.69% by HPLC (A: 0.1% FA in H<sub>2</sub>O; B: 0.1% FA in CH<sub>3</sub>CN, graded: 20â€"100%), t<sub>R</sub> 11.660â€‰min, Î»: 250â€‰nm.</p> </div> </div> <div class="generalproceduretosynthesisecompounds9aâ€" title="sec"><span class="label" tagx="label" title="label">2.1.6.</span><div class="title" tagx="title" title="title">
General procedure to synthesise compounds 9aâ€"k</div> <p>A mixture of the required compound <b>4</b> (2.3â€‰mmol) and aminoguanidine hydrochloride (2â€‰mmol) in ethanol (20â€‰ml) in the presence of 5 drops of concentrated hydrochloric acid was stirred at 50â€"60â€‰Â°C for 8â€"12â€‰h. The solvent was then removed under reduced pressure. The crude products were purified by silica gel column chromatography using dichloromethane:methanol (10:1) as the eluent.</p> <div class="(e)-2-((9-methyl-9h-carbazol-3-yl)methylene)hydrazine-1-carboximidamide(9a)" title="sec"><span class="label" tagx="label" title="label">2.1.6.1.</span><div class="title" tagx="title" title="title">
(E)-2-((9-Methyl-9H-carbazol-3-yl)methylene)hydrazine-1-carboximidamide (9a)</div> <p>White powder; yield 52.3%; m.p. 199.1-200.8â€‰Â°C. IR (KBr) cm<sup>âˆ’1</sup>: 3330, 3147 (NH<sub>2</sub>, NH), 1629 (Câ€‰=â€‰N). <sup>1</sup>H NMR (300â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 11.89 (br s, 1H, NH), 8.63 (s, 1H, CHâ€‰=â€‰N), 8.33 (s, 1H, Ar-H), 8.18 (d, 1H, <i>J</i>â€‰=â€‰8.0â€‰Hz, Ar-H), 8.05 (d, 1H, <i>J</i>â€‰=â€‰8.4â€‰Hz, Ar-H), 7.91â€"7.46 (m, 6H, Ar-H and NH), 7.29 (d, 1H, <i>J</i>â€‰=â€‰7.5â€‰Hz, Ar-H), 3.94 (s, 3H, CH<sub>3</sub>). <sup>13â€‰</sup>C NMR (75â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 155.41, 147.77, 141.81, 141.07, 126.20, 125.14, 124.36, 122.08, 121.96, 120.59, 120.36, 119.41, 109.53, 109.40, 29.16. HRMS (MALDI) calcd for C<sub>15</sub>H<sub>15</sub>N<sub>5</sub> [Mâ€‰+â€‰H]<sup>+</sup>: 266.1400, found: 266.1405.</p> </div> <div class="(e)-2-((9-ethyl-9h-carbazol-3-yl)methylene)hydrazine-1-carboximidamide(9b)" title="sec"><span class="label" tagx="label" title="label">2.1.6.2.</span><div class="title" tagx="title" title="title">
(E)-2-((9-Ethyl-9H-carbazol-3-yl)methylene)hydrazine-1-carboximidamide (9b)</div> <p>White powder; yield 59.2%; m.p. 199.4â€"200.5â€‰Â°C. IR (KBr) cm<sup>âˆ’1</sup>: 3354, 3120 (NH<sub>2</sub>, NH), 1628 (Câ€‰=â€‰N). <sup>1</sup>H NMR (300â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 11.85 (br s, 1H, NH), 8.63 (s, 1H, CHâ€‰=â€‰N), 8.33 (d, 1H, <i>J</i>â€‰=â€‰1.9â€‰Hz, Ar-H), 8.18 (d, 1H, <i>J</i>â€‰=â€‰7.7â€‰Hz, Ar-H), 8.03 (d, 1H, <i>J</i>â€‰=â€‰8.6â€‰Hz, Ar-H), 7.77â€"7.46 (m, 6H, Ar-H and NH), 7.27 (t, 1H, <i>J</i>â€‰=â€‰7.3â€‰Hz, Ar-H), 4.49 (q, 2H, <i>J</i>â€‰=â€‰6.9â€‰Hz, CH<sub>2</sub>), 1.33 (t, 3H, <i>J</i>â€‰=â€‰7.1â€‰Hz, CH<sub>3</sub>). <sup>13â€‰</sup>C NMR (75â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 155.42, 147.76, 140.83, 140.04, 131.54, 128.68, 126.26, 125.23, 124.44, 122.31, 120.72, 120.53, 119.42, 109.56, 109.40, 37.18, 18.68. HRMS (MALDI) calcd for C<sub>16</sub>H<sub>17</sub>N<sub>5</sub> [Mâ€‰+â€‰H]<sup>+</sup>: 280.1557, found: 280.1548.</p> </div> <div class="(e)-2-((9-benzyl-9h-carbazol-3-yl)methylene)hydrazine-1-carboximidamide(9c)" title="sec"><span class="label" tagx="label" title="label">2.1.6.3.</span><div class="title" tagx="title" title="title">
(E)-2-((9-Benzyl-9H-carbazol-3-yl)methylene)hydrazine-1-carboximidamide (9c)</div> <p>White powder; yield 63.1%; m.p. 271.0â€"272.4â€‰Â°C. IR (KBr) cm<sup>âˆ’1</sup>: 3319, 3154 (NH<sub>2</sub>, NH), 1600 (Câ€‰=â€‰N). <sup>1</sup>H NMR (300â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 11.91 (br s, 1H, NH), 8.67 (s, 1H, CHâ€‰=â€‰N), 8.34 (s, 1H, Ar-H), 8.21 (d, 1H, <i>J</i>â€‰=â€‰7.7â€‰Hz, Ar-H), 8.01 (d, 1H, <i>J</i>â€‰=â€‰8.5â€‰Hz, Ar-H), 7.84â€"7.65 (m, 5H, Ar-H and NH), 7.47 (t, 1H, <i>J</i>â€‰=â€‰7.7â€‰Hz, Ar-H), 7.24 (dt, 6H, <i>J</i>â€‰=â€‰18.8, 7.5â€‰Hz, Ar-H), 5.71 (s, 2H, CH<sub>2</sub>). <sup>13â€‰</sup>C NMR (75â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 155.82, 148.14, 141.94, 141.09, 137.95, 132.14, 131.97, 129.05, 127.80, 127.21, 126.85, 125.85, 125.26, 122.87, 122.73, 121.10, 120.99, 120.21, 110.50, 110.33, 46.20. HRMS (MALDI) calcd for C<sub>21</sub>H<sub>19</sub>N<sub>5</sub> [Mâ€‰+â€‰H]<sup>+</sup>: 342.1713, found: 342.1701.</p> </div> <div class="(e)-2-((9-(4-methylbenzyl)-9h-carbazol-3-yl)methylene)hydrazine-1-carboximidamide(9d)" title="sec"><span class="label" tagx="label" title="label">2.1.6.4.</span><div class="title" tagx="title" title="title">
(E)-2-((9-(4-Methylbenzyl)-9H-carbazol-3-yl)methylene)hydrazine-1-carboximidamide (9d)</div> <p>White powder; yield 45.0%; m.p. 295.5â€"298.0â€‰Â°C. IR (KBr) cm<sup>âˆ’1</sup>: 3382, 3134 (NH<sub>2</sub>, NH), 1629 (Câ€‰=â€‰N). <sup>1</sup>H NMR (300â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 11.82 (br s, 1H, NH), 8.59 (s, 1H, CHâ€‰=â€‰N), 8.25 (s, 1H, Ar-H), 8.13 (d, 1H, <i>J</i>â€‰=â€‰7.7â€‰Hz, Ar-H), 7.94 (dd, 1H, <i>J</i>â€‰=â€‰8.7, 1.6â€‰Hz, Ar-H), 7.75â€"7.58 (m, 4H, Ar-H and NH), 7.40 (t, 2H, <i>J</i>â€‰=â€‰7.7â€‰Hz, Ar-H), 7.20 (t, 1H, <i>J</i>â€‰=â€‰7.4â€‰Hz, Ar-H), 7.01 (s, 4H, Ar-H), 5.59 (s, 2H, CH<sub>2</sub>), 2.14 (s, 3H, CH<sub>3</sub>). <sup>13â€‰</sup>C NMR (75â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 155.46, 147.63, 141.47, 140.63, 136.53, 134.46, 129.14 (2â€‰C), 126.81 (2â€‰C), 126.37, 125.39, 124.78, 122.43, 122.30, 120.65, 120.54, 119.71, 110.09, 109.91, 45.56, 20.63. HRMS (MALDI) calcd for C<sub>22</sub>H<sub>21</sub>N<sub>5</sub> [Mâ€‰+â€‰H]<sup>+</sup>: 356.1869, found: 356.1854. Purity: 96.74% by HPLC (A: 0.1% FA in H<sub>2</sub>O; B: 0.1% FA in CH<sub>3</sub>CN, graded: 20â€"100%), t<sub>R</sub> 11.533â€‰min, Î»: 250â€‰nm.</p> </div> <div class="(e)-2-((9-(2-fluorobenzyl)-9h-carbazol-3-yl)methylene)hydrazine-1-carboximidamide(9e)" title="sec"><span class="label" tagx="label" title="label">2.1.6.5.</span><div class="title" tagx="title" title="title">
(E)-2-((9-(2-Fluorobenzyl)-9H-carbazol-3-yl)methylene)hydrazine-1-carboximidamide (9e)</div> <p>White powder; yield 39.3%; m.p. 248.3â€"249.9â€‰Â°C. IR (KBr) cm<sup>âˆ’1</sup>: 3356, 3163 (NH<sub>2</sub>, NH), 1637 (Câ€‰=â€‰N). <sup>1</sup>H NMR (300â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 11.88 (s, 1H, NH<sub>2</sub>), 8.67 (s, 1H, CHâ€‰=â€‰N), 8.32 (s, 1H, Ar-H), 8.21 (d, 1H, <i>J</i>â€‰=â€‰7.8â€‰Hz, Ar-H), 8.02 (dd, 1H, <i>J</i>â€‰=â€‰8.7, 1.6â€‰Hz, Ar-H), 7.89â€"7.41 (m, 6H, Ar-H and NH), 7.37â€"7.19 (m, 3H, Ar-H), 7.04 (td, 1H, <i>J</i>â€‰=â€‰7.4, 1.4â€‰Hz, Ar-H), 6.89 (td, 1H, <i>J</i>â€‰=â€‰7.7, 1.7â€‰Hz, Ar-H), 5.77 (d, 2H, <i>J</i>â€‰=â€‰2.2â€‰Hz, CH<sub>2</sub>). <sup>13â€‰</sup>C NMR (75â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 161.68, 158.43, 155.40, 147.52, 141.38, 140.51, 128.75 (d, 1â€‰C, <i>J</i>â€‰=â€‰4.1â€‰Hz), 126.40, 125.36, 124.93, 124.57 (d, 1â€‰C, <i>J</i>â€‰=â€‰3.3â€‰Hz), 124.12, 123.92, 122.43, 122.30, 120.58 (d, 1â€‰C, <i>J</i>â€‰=â€‰8.3â€‰Hz), 119.85, 115.67, 115.39, 109.89 (d, 1â€‰C, <i>J</i>â€‰=â€‰8.6â€‰Hz), 65.01. HRMS (MALDI) calcd for C<sub>21</sub>H<sub>18</sub>FN<sub>5</sub> [Mâ€‰+â€‰H]<sup>+</sup>: 360.1619, found: 360.1611.</p> </div> <div class="(e)-2-((9-(2,4-dichlorobenzyl)-9h-carbazol-3-yl)methylene)hydrazine-1-carboximidamide(9f)" title="sec"><span class="label" tagx="label" title="label">2.1.6.6.</span><div class="title" tagx="title" title="title">
(E)-2-((9-(2,4-Dichlorobenzyl)-9H-carbazol-3-yl)methylene)hydrazine-1-carboximidamide (9f)</div> <p>White powder; yield 58.2%; m.p. 240.7â€"242.8â€‰Â°C. IR (KBr) cm<sup>âˆ’1</sup>: 3397, 3146 (NH<sub>2</sub>, NH), 1629 (Câ€‰=â€‰N). <sup>1</sup>H NMR (300â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 12.12 (br s, 1H, NH), 8.71 (s, 1H, CHâ€‰=â€‰N), 8.35 (s, 1H, Ar-H), 8.24 (d, 1H, <i>J</i>â€‰=â€‰7.7â€‰Hz, Ar-H), 8.11â€"7.66 (m, 5H, Ar-H and NH), 7.59 (d, 1H, <i>J</i>â€‰=â€‰8.6â€‰Hz, Ar-H), 7.54â€"7.41 (m, 2H, Ar-H), 7.29 (t, 1H, <i>J</i>â€‰=â€‰7.3â€‰Hz, Ar-H), 7.19 (dd, 1H, <i>J</i>â€‰=â€‰8.3, 2.3â€‰Hz, Ar-H), 6.41 (d, 1H, <i>J</i>â€‰=â€‰8.4â€‰Hz, Ar-H), 5.75 (s, 2H, CH<sub>2</sub>). <sup>13â€‰</sup>C NMR (75â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 155.52, 147.63, 141.45, 140.55, 133.66, 132.83, 132.76, 129.13, 128.66, 127.72, 126.61, 125.56, 125.24, 122.63, 122.46, 120.74, 120.68, 120.12, 109.83, 109.73, 43.59. HRMS (MALDI) calcd for C<sub>21</sub>H<sub>17</sub>Cl<sub>2</sub>N<sub>5</sub> [Mâ€‰+â€‰H]<sup>+</sup>: 410.0934, found: 410.0932.</p> </div> <div class="(e)-2-((9-(2-chlorobenzyl)-9h-carbazol-3-yl)methylene)hydrazine-1-carboximidamide(9â€‰g)" title="sec"><span class="label" tagx="label" title="label">2.1.6.7.</span><div class="title" tagx="title" title="title">
(E)-2-((9-(2-Chlorobenzyl)-9H-carbazol-3-yl)methylene)hydrazine-1-carboximidamide (9â€‰g)</div> <p>White powder; yield 45.4%; m.p. 249.7â€"250.4â€‰Â°C. IR (KBr) cm<sup>âˆ’1</sup>: 3386, 3159 (NH<sub>2</sub>, NH), 1629 (Câ€‰=â€‰N). <sup>1</sup>H NMR (300â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 11.88 (br s, 1H, NH), 8.70 (s, 1H, CHâ€‰=â€‰N), 8.33 (s, 1H, Ar-H), 8.24 (d, 1H, <i>J</i>â€‰=â€‰7.6â€‰Hz, Ar-H), 8.00 (dd, <i>J</i>â€‰=â€‰8.6, 1H, 1.7â€‰Hz, Ar-H), 7.96â€"7.43 (m, 7H, Ar-H and NH), 7.37â€"7.24 (m, 2H, Ar-H), 7.18â€"7.06 (m, 1H, Ar-H), 6.51â€"6.40 (m, 1H, Ar-H), 5.77 (s, 2H, CH<sub>2</sub>). <sup>13â€‰</sup>C NMR (75â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 155.88, 147.98, 141.96, 141.05, 134.82, 132.26, 130.10, 129.55, 127.95, 127.71, 126.99, 125.94, 125.55, 122.97, 122.83, 121.20, 121.10, 120.45, 110.29, 110.18, 44.30. HRMS (MALDI) calcd for C<sub>21</sub>H<sub>18</sub>ClN<sub>5</sub> [Mâ€‰+â€‰H]<sup>+</sup>: 376.1326, found: 376.1322.</p> </div> <div class="(e)-2-((9-(3-chlorobenzyl)-9h-carbazol-3-yl)methylene)hydrazine-1-carboximidamide(9â€‰h)" title="sec"><span class="label" tagx="label" title="label">2.1.6.8.</span><div class="title" tagx="title" title="title">
(E)-2-((9-(3-Chlorobenzyl)-9H-carbazol-3-yl)methylene)hydrazine-1-carboximidamide (9â€‰h)</div> <p>White powder; yield 41.5%; m.p. 256.1â€"257.5â€‰Â°C. IR (KBr) cm<sup>âˆ’1</sup>: 3389, 3137 (NH<sub>2</sub>, NH), 1634 (Câ€‰=â€‰N). <sup>1</sup>H NMR (300â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 11.93 (s, 1H, NH), 8.68 (s, 1H, CHâ€‰=â€‰N), 8.33 (s, 1H, Ar-H), 8.22 (d, 1H, <i>J</i>â€‰=â€‰7.7â€‰Hz, Ar-H), 8.09â€"7.58 (m, 6H, Ar-H and NH), 7.49 (t, 1H, <i>J</i>â€‰=â€‰7.7â€‰Hz, Ar-H), 7.29 (t, 4H, <i>J</i>â€‰=â€‰6.0â€‰Hz, Ar-H), 7.08 (dd, 1H, <i>J</i>â€‰=â€‰6.6, 3.1â€‰Hz, Ar-H), 5.75 (s, 2H, CH<sub>2</sub>). <sup>13â€‰</sup>C NMR (75â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 155.89, 148.00, 141.82, 140.97, 140.57, 133.66, 131.02, 127.81, 127.07, 126.96, 125.94, 125.83, 125.46, 122.91, 122.77, 121.19, 121.07, 120.38, 110.43, 110.28, 45.59. HRMS (MALDI) calcd for C<sub>21</sub>H<sub>18</sub>ClN<sub>5</sub> [Mâ€‰+â€‰H]<sup>+</sup>: 376.1326, found: 376.1319.</p> </div> <div class="(e)-2-((9-(4-chlorobenzyl)-9h-carbazol-3-yl)methylene)hydrazine-1-carboximidamide(9i)" title="sec"><span class="label" tagx="label" title="label">2.1.6.9.</span><div class="title" tagx="title" title="title">
(E)-2-((9-(4-Chlorobenzyl)-9H-carbazol-3-yl)methylene)hydrazine-1-carboximidamide (9i)</div> <p>White powder; yield 38.7%; m.p. 239.5â€"240.8â€‰Â°C. IR (KBr) cm<sup>âˆ’1</sup>: 3266, 3057 (NH<sub>2</sub>, NH), 1629 (Câ€‰=â€‰N). <sup>1</sup>H NMR (300â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 12.07 (br s, 1H, NH), 8.68 (s, 1H, CHâ€‰=â€‰N), 8.35 (d, 1H, <i>J</i>â€‰=â€‰5.4â€‰Hz, Ar-H), 8.21 (d, 1H, <i>J</i>â€‰=â€‰7.7â€‰Hz, Ar-H), 8.01 (d, 1H, <i>J</i>â€‰=â€‰8.3â€‰Hz, Ar-H), 7.68 (m, 5H, Ar-H and NH), 7.47 (t, 1H, <i>J</i>â€‰=â€‰7.7â€‰Hz, Ar-H), 7.38â€"7.24 (m, 3H, Ar-H), 7.18 (d, 2H, <i>J</i>â€‰=â€‰8.7â€‰Hz, Ar-H), 5.72 (s, 2H, CH<sub>2</sub>). <sup>13â€‰</sup>C NMR (75â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 155.44, 147.58, 141.38, 140.53, 136.56, 131.96, 128.66 (2â€‰C), 128.62 (2â€‰C), 126.48, 125.47, 124.96, 122.49, 122.35, 120.72, 120.62, 119.88, 110.02, 109.86, 45.08. HRMS (MALDI) calcd for C<sub>21</sub>H<sub>18</sub>ClN<sub>5</sub> [Mâ€‰+â€‰H]<sup>+</sup>: 376.1326, found: 376.1329.</p> </div> <div class="(e)-2-((9-(4-bromobenzyl)-9h-carbazol-3-yl)methylene)hydrazine-1-carboximidamide(9j)" title="sec"><span class="label" tagx="label" title="label">2.1.6.10.</span><div class="title" tagx="title" title="title">
(E)-2-((9-(4-Bromobenzyl)-9H-carbazol-3-yl)methylene)hydrazine-1-carboximidamide (9j)</div> <p>White powder; yield 41.1%; m.p. 239.5â€"240.7â€‰Â°C. IR (KBr) cm<sup>âˆ’1</sup>: 3377, 3161 (NH<sub>2</sub>, NH), 1629 (Câ€‰=â€‰N). <sup>1</sup>H NMR (300â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 11.86 (s, 1H, NH), 8.67 (s, 1H, CHâ€‰=â€‰N), 8.32 (s, 1H, Ar-H), 8.21 (d, 1H, <i>J</i>â€‰=â€‰7.7â€‰Hz, Ar-H), 8.09â€"7.98 (m, 1H, Ar-H), 7.97â€"7.56 (m, 5H, Ar-H and NH), 7.48 (dt, 3H, <i>J</i>â€‰=â€‰7.0, 3.5â€‰Hz, Ar-H), 7.29 (t, 1H, <i>J</i>â€‰=â€‰7.5â€‰Hz, Ar-H), 7.13 (d, 2H, <i>J</i>â€‰=â€‰8.5â€‰Hz, Ar-H), 5.72 (s, 2H, CH<sub>2</sub>). <sup>13â€‰</sup>C NMR (75â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 155.43, 147.62, 141.39, 140.54, 136.98, 131.54 (2â€‰C), 129.00 (2â€‰C), 126.49, 125.48, 124.96, 122.49, 122.35, 120.71, 120.61, 120.46, 119.89, 110.02, 109.85, 45.16. HRMS (MALDI) calcd for C<sub>21</sub>H<sub>18</sub>BrN<sub>5</sub> [Mâ€‰+â€‰H]<sup>+</sup>: 420.0818, found: 420.0829.</p> </div> <div class="(e)-2-((9-(4-cyanobenzyl)-9h-carbazol-3-yl)methylene)hydrazine-1-carboximidamide(9k)" title="sec"><span class="label" tagx="label" title="label">2.1.6.11.</span><div class="title" tagx="title" title="title">
(E)-2-((9-(4-Cyanobenzyl)-9H-carbazol-3-yl)methylene)hydrazine-1-carboximidamide (9k)</div> <p>White powder; yield 45.7%; m.p. 240.6â€"243.9â€‰Â°C. IR (KBr) cm<sup>âˆ’1</sup>: 3300, 3123 (NH<sub>2</sub>, NH), 1631 (Câ€‰=â€‰N). <sup>1</sup>H NMR (300â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 11.92 (br s, 1H, NH), 8.68 (s, 1H, CHâ€‰=â€‰N), 8.33 (s, 1H, Ar-H), 8.22 (d, 1H, <i>J</i>â€‰=â€‰7.7â€‰Hz, Ar-H), 8.17â€"7.55 (m, 8H, Ar-H and NH), 7.48 (t, 1H, <i>J</i>â€‰=â€‰7.7â€‰Hz, Ar-H), 7.30 (dd, 3H, <i>J</i>â€‰=â€‰7.9, 2.2â€‰Hz, Ar-H), 5.85 (s, 2H, CH<sub>2</sub>). <sup>13â€‰</sup>C NMR (75â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 155.31, 147.68, 143.30, 141.37, 140.50, 132.61 (2â€‰C), 127.56 (2â€‰C), 126.60, 125.57, 125.09, 122.54, 122.35, 120.71 (2â€‰C), 120.05, 118.65, 110.15, 109.91, 109.79, 45.43. HRMS (MALDI) calcd for C<sub>22</sub>H<sub>18</sub>N<sub>6</sub> [Mâ€‰+â€‰H]<sup>+</sup>: 367.1666, found: 367.1656.</p> </div> </div> <div class="generalproceduretosynthesisecompounds10aâ€" title="sec"><span class="label" tagx="label" title="label">2.1.7.</span><div class="title" tagx="title" title="title">
General procedure to synthesise compounds 10aâ€"b and 11</div> <p>A mixture of the required compound <b>4</b> (2â€‰mmol) and either thiosemicarbazide hydrochloride or semicarbazide hydrochloride(2â€‰mmol) in ethanol (20â€‰ml) was stirred at 50â€"60â€‰Â°C for 8â€"12â€‰h in the presence of five drops of concentrated hydrochloric acid. The solution was evaporated to dryness under reduced pressure, and the residue was purified by silica gel column chromatography using dichloromethane:methanol (80:1) as the eluent.</p> <div class="(e)-2-((9-methyl-9h-carbazol-3-yl)methylene)hydrazine-1-carbothioamide(10a)" title="sec"><span class="label" tagx="label" title="label">2.1.7.1.</span><div class="title" tagx="title" title="title">
(E)-2-((9-Methyl-9H-carbazol-3-yl)methylene)hydrazine-1-carbothioamide (10a)</div> <p>White solid; yield 60.5%; m.p. 222.4â€"223.8â€‰Â°C. IR (KBr) cm<sup>âˆ’1</sup>: 3238, 3026 (NH<sub>2</sub>, NH), 1630 (Câ€‰=â€‰N), 1120 (Câ€‰=â€‰S). <sup>1</sup>H NMR (300â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 11.42 (s, 1H, NH), 8.59 (s, 1H, CHâ€‰=â€‰N), 8.21 (d, 3H, <i>J</i>â€‰=â€‰7.8â€‰Hz, Ar-H), 8.08â€"7.89 (m, 2H, NH<sub>2</sub>), 7.62 (d, 2H, <i>J</i>â€‰=â€‰8.6â€‰Hz, Ar-H), 7.50 (t, 1H, <i>J</i>â€‰=â€‰7.6â€‰Hz, Ar-H), 7.25 (t, 1H, <i>J</i>â€‰=â€‰7.4â€‰Hz, Ar-H), 3.90 (s, 3H, CH<sub>3</sub>). <sup>13â€‰</sup>C NMR (75â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 177.45, 143.65, 141.54, 141.02, 126.11, 125.11, 125.02, 122.19, 122.00, 120.47, 120.19, 119.30, 109.41, 109.36, 29.09. HRMS (MALDI) calcd for C<sub>15</sub>H<sub>14</sub>N<sub>4</sub>S [Mâ€‰+â€‰H]<sup>+</sup>: 283.1012, found: 283.1020.</p> </div> <div class="(e)-2-((9-ethyl-9h-carbazol-3-yl)methylene)hydrazine-1-carbothioamide(10â€‰b)" title="sec"><span class="label" tagx="label" title="label">2.1.7.2.</span><div class="title" tagx="title" title="title">
(E)-2-((9-Ethyl-9H-carbazol-3-yl)methylene)hydrazine-1-carbothioamide (10â€‰b)</div> <p>White solid; yield 64.6%; m.p. 199.8â€"202.0â€‰Â°C. IR (KBr) cm<sup>âˆ’1</sup>: 3280, 3043 (NH<sub>2</sub>, NH), 1594 (Câ€‰=â€‰N), 1200 (Câ€‰=â€‰S). <sup>1</sup>H NMR (300â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 11.40 (s, 1H, NH), 8.58 (s, 1H, CHâ€‰=â€‰N), 8.27â€"8.13 (m, 3H, Ar-H), 8.04â€"7.91 (m, 2H, Ar-H), 7.64 (s, 1H, NH<sub>2</sub>), 7.61 (s, 1H, NH<sub>2</sub>), 7.53â€"7.44 (m, 1H, Ar-H), 7.24 (t, 1H, <i>J</i>â€‰=â€‰7.4â€‰Hz, Ar-H), 4.45 (q, 2H, <i>J</i>â€‰=â€‰6.9â€‰Hz, CH<sub>2</sub>), 1.32 (t, 3H, <i>J</i>â€‰=â€‰6.8â€‰Hz, CH<sub>3</sub>). <sup>13â€‰</sup>C NMR (75â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 177.45, 143.56, 140.52, 139.96, 126.12, 125.13, 125.08, 122.39, 122.21, 120.61, 120.24, 119.25, 109.39, 109.29, 37.10, 18.64. HRMS (MALDI) calcd for C<sub>16</sub>H<sub>16</sub>N<sub>4</sub>S [Mâ€‰+â€‰H]<sup>+</sup>: 297.1168, found: 297.1161.</p> </div> <div class="(e)-2-((9-ethyl-9h-carbazol-3-yl)methylene)hydrazine-1-carboxamide(11)" title="sec"><span class="label" tagx="label" title="label">2.1.7.3.</span><div class="title" tagx="title" title="title">
(E)-2-((9-Ethyl-9H-carbazol-3-yl)methylene)hydrazine-1-carboxamide (11)</div> <p>White solid; yield 42.3%; m.p. 211.1â€"212.0â€‰Â°C. IR (KBr) cm<sup>âˆ’1</sup>: 3343, 3049 (NH<sub>2</sub>, NH), 1691 (Câ€‰=â€‰O), 1595 (Câ€‰=â€‰N). <sup>1</sup>H NMR (300â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 10.17 (s, 1H, NH), 8.51 (s, 1H, CHâ€‰=â€‰N), 8.20 (d, 1H, <i>J</i>â€‰=â€‰7.7â€‰Hz, Ar-H), 8.01 (s, 1H, Ar-H), 7.86 (d, 1H, <i>J</i>â€‰=â€‰8.5â€‰Hz, Ar-H), 7.61 (dd, 2H, <i>J</i>â€‰=â€‰8.4, 3.7â€‰Hz, Ar-H), 7.47 (t, 1H, <i>J</i>â€‰=â€‰7.7â€‰Hz, Ar-H), 7.23 (t, 1H, <i>J</i>â€‰=â€‰7.4â€‰Hz, Ar-H), 6.52 (br s, 2H, NH<sub>2</sub>), 4.46 (q, 2H, <i>J</i>â€‰=â€‰7.0â€‰Hz, CH<sub>2</sub>), 1.32 (t, 3H, <i>J</i>â€‰=â€‰6.9â€‰Hz, CH<sub>3</sub>). <sup>13â€‰</sup>C NMR (75â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 157.03, 140.48, 140.05, 139.93, 126.01, 125.89, 124.46, 122.33, 122.22, 120.58, 119.22, 119.08, 109.31, 109.19, 37.06, 13.72. HRMS (MALDI) calcd for C<sub>16</sub>H<sub>16</sub>N<sub>4</sub>O [Mâ€‰+â€‰H]<sup>+</sup>: 281.1397, found: 281.1392.</p> </div> </div> <div class="generalprocedureforthesynthesisofcompounds12aâ€" title="sec"><span class="label" tagx="label" title="label">2.1.8.</span><div class="title" tagx="title" title="title">
General procedure for the synthesis of compounds 12aâ€"12d</div> <p>The intermediate <b>4</b> (2â€‰mmol) reacted with isonicotinic acid hydrazide (2â€‰mmol) in the presence of catalytic amounts of hydrochloric acid (5 drops) in ethanol (20â€‰ml) at 70â€‰Â°C for 5â€‰h. The solution was evaporated to dryness under reduced pressure, and the residue was purified by silica gel column chromatography with (dichloromethane: methanol = 60:1).</p> <div class="(e)-n'-((9-benzyl-9h-carbazol-3-yl)methylene)isonicotinohydrazide(12a)" title="sec"><span class="label" tagx="label" title="label">2.1.8.1.</span><div class="title" tagx="title" title="title">
(E)-N'-((9-Benzyl-9H-carbazol-3-yl)methylene)isonicotinohydrazide (12a)</div> <p>Yellow solid; yield 80.0%; m.p. 198.0â€"199.5â€‰Â°C. IR (KBr) cm<sup>âˆ’1</sup>: 3250, 3046 (NH), 1646 (Câ€‰=â€‰O), 1601 (Câ€‰=â€‰N). <sup>1</sup>H NMR (300â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 12.02 (s, 1H, NH), 8.90â€"8.73 (m, 2H, Ar-H), 8.65 (s, 1H, CHâ€‰=â€‰N), 8.55 (s, 1H, Ar-H), 8.31 (dd, 1H, <i>J</i>â€‰=â€‰9.6, 6.5â€‰Hz, Ar-H), 7.97â€"7.63 (m, 5H, Ar-H and pyridine-H), 7.48 (dd, 1H, <i>J</i>â€‰=â€‰10.7, 4.7â€‰Hz, Ar-H), 7.38â€"7.06 (m, 6H, Ar-H), 5.73 (s, 2H, CH<sub>2</sub>). <sup>13â€‰</sup>C NMR (75â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 161.44, 150.29 (2â€‰C), 141.50, 140.77, 140.70, 137.43, 128.59 (2â€‰C), 127.32 (2â€‰C), 126.70 (2â€‰C), 126.40, 125.41, 125.04, 122.60, 122.25, 121.54 (2â€‰C), 120.69, 120.29, 119.74, 110.03, 109.92, 45.81. HRMS (MALDI) calcd for C<sub>26</sub>H<sub>20</sub>N<sub>4</sub>O [Mâ€‰+â€‰H]<sup>+</sup>: 405.1710, found: 405.1719.</p> </div> <div class="(e)-n'-((9-(4-methylbenzyl)-9h-carbazol-3-yl)methylene)isonicotinohydrazide(12â€‰b)" title="sec"><span class="label" tagx="label" title="label">2.1.8.2.</span><div class="title" tagx="title" title="title">
(E)-N'-((9-(4-Methylbenzyl)-9H-carbazol-3-yl)methylene)isonicotinohydrazide (12â€‰b)</div> <p>Yellow solid; yield 74.7%; m.p. 196.0â€"197.8â€‰Â°C. IR (KBr) cm<sup>âˆ’1</sup>: 3320, 3060 (NH), 1647 (Câ€‰=â€‰O), 1595 (Câ€‰=â€‰N). <sup>1</sup>H NMR (300â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 12.02 (s, 1H, NH), 8.80 (d, 2H, <i>J</i>â€‰=â€‰5.0â€‰Hz, Ar-H), 8.63 (s, 1H, CHâ€‰=â€‰N), 8.54 (s, 1H, pyridineâ€"H), 8.29 (d, 1H, <i>J</i>â€‰=â€‰7.4â€‰Hz, pyridineâ€"H), 7.95â€"7.81 (m, 3H, Ar-H), 7.71 (dd, 2H, <i>J</i>â€‰=â€‰23.9, 8.3â€‰Hz, pyridineâ€"H), 7.48 (t, 1H, <i>J</i>â€‰=â€‰7.6â€‰Hz, Ar-H), 7.27 (t, 1H, <i>J</i>â€‰=â€‰7.4â€‰Hz, Ar-H), 7.09 (s, 4H, Ar-H), 5.66 (s, 2H, CH<sub>2</sub>), 2.22 (s, 3H, CH<sub>3</sub>). <sup>13â€‰</sup>C NMR (75â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 161.40, 150.29 (2â€‰C), 150.21, 141.43, 140.72, 140.63, 136.52, 134.40, 129.13 (2â€‰C), 126.73 (2â€‰C), 126.37, 125.28, 124.95, 122.52, 122.19, 121.57, 120.69, 120.33, 119.68, 110.08, 109.97, 45.53, 20.58. HRMS (MALDI) calcd for C<sub>27</sub>H<sub>22</sub>N<sub>4</sub>O [Mâ€‰+â€‰H]<sup>+</sup>: 419.1866, found: 419.1854.</p> </div> <div class="(e)-n'-((9-(2-fluorobenzyl)-9h-carbazol-3-yl)methylene)isonicotinohydrazide(12c)" title="sec"><span class="label" tagx="label" title="label">2.1.8.3.</span><div class="title" tagx="title" title="title">
(E)-N'-((9-(2-Fluorobenzyl)-9H-carbazol-3-yl)methylene)isonicotinohydrazide (12c)</div> <p>Yellow solid; yield 73.8%; m.p. 220.3â€"221.5â€‰Â°C. IR (KBr) cm<sup>âˆ’1</sup>: 3366, 3050 (NH), 1651 (Câ€‰=â€‰O), 1589 (Câ€‰=â€‰N). <sup>1</sup>H NMR (300â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 12.07 (s, 1H, NH), 8.82 (s, 2H, Ar-H), 8.68 (s, 1H, CHâ€‰=â€‰N), 8.57 (s, 1H, pyridineâ€"H), 8.26 (s, 1H, pyridineâ€"H), 8.00â€"7.83 (m, 3H, Ar-H), 7.66 (dd, 2H, <i>J</i>â€‰=â€‰26.4, 8.4â€‰Hz, pyridineâ€"H), 7.46 (t, 1H, <i>J</i>â€‰=â€‰7.6â€‰Hz, Ar-H), 7.35â€"7.16 (m, 3H, Ar-H), 7.00 (t, 1H, <i>J</i>â€‰=â€‰7.2â€‰Hz, Ar-H), 6.89 (t, 1H, <i>J</i>â€‰=â€‰7.7â€‰Hz, Ar-H), 5.74 (s, 2H, CH<sub>2</sub>). <sup>13â€‰</sup>C NMR (75â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 161.68, 161.43, 150.29 (2â€‰C), 150.14, 141.38, 140.70, 140.55, 129.53 (d, 1â€‰C, <i>J</i>â€‰=â€‰8.1â€‰Hz), 128.66 (d, 1â€‰C, <i>J</i>â€‰=â€‰4.3â€‰Hz), 126.44, 125.48, 125.05, 124.58 (d, 1â€‰C, <i>J</i>â€‰=â€‰3.4â€‰Hz), 122.59, 122.24, 121.56 (2â€‰C), 120.71, 120.28, 119.86, 115.67, 115.39, 110.03, 109.86, 40.23. HRMS (MALDI) calcd for C<sub>26</sub>H<sub>19</sub>FN<sub>4</sub>O [Mâ€‰+â€‰H]<sup>+</sup>: 423.1616, found: 423.1612.</p> </div> <div class="(e)-n'-((9-(2,4-dichlorobenzyl)-9h-carbazol-3-yl)methylene)isonicotinohydrazide(12d)" title="sec"><span class="label" tagx="label" title="label">2.1.8.4.</span><div class="title" tagx="title" title="title">
(E)-N'-((9-(2,4-Dichlorobenzyl)-9H-carbazol-3-yl)methylene)isonicotinohydrazide (12d)</div> <p>Yellow solid; yield 64.2%; m.p. 209.1â€"210.3â€‰Â°C. IR (KBr) cm<sup>âˆ’1</sup>: 3400, 3137 (NH), 1657 (Câ€‰=â€‰O), 1597 (Câ€‰=â€‰N). <sup>1</sup>H NMR (300â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 12.04 (s, 1H, NH), 8.88â€"8.73 (m, 2H, Ar-H), 8.64 (s, 1H, CHâ€‰=â€‰N), 8.58 (d, 1H, <i>J</i>â€‰=â€‰1.6â€‰Hz, pyridineâ€"H), 8.33 (d, 1H, <i>J</i>â€‰=â€‰7.7â€‰Hz, pyridineâ€"H), 7.96â€"7.69 (m, 4H, Ar-H and pyridineâ€"H), 7.68â€"7.17 (m, 5H, Ar-H), 6.42 (d, 1H, <i>J</i>â€‰=â€‰8.4â€‰Hz, Ar-H), 5.76 (s, 2H, CH<sub>2</sub>). <sup>13â€‰</sup>C NMR (75â€‰MHz, DMSO-<i>d</i><sub>6</sub>, ppm) <i>Î´</i> 161.38, 150.28 (2â€‰C), 150.01, 141.34, 140.67, 140.50, 133.60, 132.73, 132.67, 129.09, 128.41, 127.68, 126.60, 125.74, 125.18, 122.67, 122.31, 121.54 (2â€‰C), 120.84, 120.34, 120.07, 109.92, 109.73, 54.91. HRMS (MALDI) calcd for C<sub>26</sub>H<sub>18</sub>Cl<sub>2</sub>N<sub>4</sub>O [Mâ€‰+â€‰H]<sup>+</sup>: 473.0930, found: 473.0941.</p> </div> </div> </div> <div class="evaluationofantibacterialactivityinÂ vitro" title="sec"><span class="label" tagx="label" title="label">2.2.</span><div class="title" tagx="title" title="title">
Evaluation of antibacterial activity inÂ vitro</div> <p>The <i>inÂ vitro</i> antimicrobial and antifungal activities of the synthesised compounds were evaluated to obtain the minimum inhibitory concentrations (MICs), using a 96-well microtiter plate and a serial dilution method. Gatifloxacin and moxifloxacin were used as positive controls and DMSO as a negative control. The micro-organisms used in the present study were two Gram-positive strains (<i>Staphylococcus aureus</i> 4220, <i>Streptococcus mutans</i> 3289), one clinical isolate of multidrug-resistant Gram-positive bacterial strain (<i>Methicillin-resistant Staphylococcus aureus CCARM</i> 3167), one Gram-negative strain (<i>Escherichia coli</i> 1924) and one fungus (<i>Candida albicans</i> 7535). The bacteria were grown to mid-log phase in Mueller-Hinton broth and diluted 1000-fold in the same medium. Stock solutions of the test compounds in dimethyl sulfoxide were prepared and then poured into 96-well plates. The final concentration of 0.5â€"64â€‰Âµg/mL underwent a twofold serial dilution<a href="#CIT0014"><sup>14</sup></a><sup>,</sup><a href="#CIT0024"><sup>24</sup></a>. The bacteria were suspended and contained approximately 10<sup>5</sup> CFU/mL. These were applied to 96-well plates with a serial dilution and incubated at 37â€‰Â°C for 24â€‰h. The bacteria growth was measured from the turbidity at 630â€‰nm using a microplate reader. All experiments were carried out in triplicate. Their MBC and MFC values were also determined (only for the compounds with MIC values of &amp;lt; 256â€‰Î¼g/mL).</p> </div> <div class="mttassay" title="sec"><span class="label" tagx="label" title="label">2.3.</span><div class="title" tagx="title" title="title">
MTT assay</div> <p>Cell viability has been determined using the 3-(4,5-dimethylthiazol-2-y1)-2,5-diphenyltetrazolium Bromide (MTT, Sigmaâ€"Aldrich, Milan, Italy) assay. Cells have been seeded on 48 well plates and grown in complete medium. Before being treated, cells have been starved in serum-free medium for 24â€‰h for allowing cell cycle synchronisation. 72â€‰h after treatments, fresh MTT, re-suspended in PBS, was added to each well (final concentration (0.5â€‰mg/mL). After 2â€‰h incubation at 37â€‰Â°C, cells have been lysed with DMSO, and then optical density was measured at 570â€‰nm using a microplate reader. At least six doses of the studied compounds, solubilised in DMSO (0.1% final concentration), have been evaluated and each experiment has been performed in triplicate. The absorbance values have been used to determine the IC<sub>50</sub> for each cell line using GraphPad Prism 5 Software (GraphPad Inc., San Diego, CA).</p> </div> <div class="dockingstudy" title="sec"><span class="label" tagx="label" title="label">2.4.</span><div class="title" tagx="title" title="title">
Docking study</div> <p>Preliminary docking was performed to evaluate whether binding to DHFR might account for the bactericidal effect of the compounds. All docking studies were carried out using Discovery Studio 2017 (Accelrys, San Diego, CA). Docking studies were performed according to our previous report<a href="#CIT0025"><sup>25</sup></a>. The crystal structure data were obtained from the protein data bank (<i>E. coli</i> DHFR PDB_ID: 1RX7). Enzyme structures were checked for missing atoms, bonds and contacts. Hydrogen atoms were added to the enzyme structure. Water molecules and bound ligands were manually deleted. Then the protein was refined with CHARMm. The structures of compounds were sketched in 2D and converted into 3D using the DS molecule editor. Automated docking studies were carried out to investigate the binding mode of compounds <b>8b</b> and <b>8f</b> utilizing DS-CDOCKER protocol. The pose with the top CDOCKER_INTERACTION_ENERGY was chosen for analysing the binding features of compounds <b>8b</b> and <b>8f</b> with DHFR.</p> </div> <div class="inhibitionofdhfractivitiesinÂ vitro" title="sec"><span class="label" tagx="label" title="label">2.5.</span><div class="title" tagx="title" title="title">
Inhibition of DHFR activities inÂ vitro</div> <p>The inhibition of DHFR activities of compound <b>8f</b> was measured using ELISA kits (Mlbio, Shanghai, China) under different concentrations (0, 0.1, 0.3, 1, 3, 10â€‰Âµmol/L), according to the manufacturerâ€™s instructions.</p> </div> </div> <div class="resultsanddiscussion" title="sec"><span class="label" tagx="label" title="label">3.</span><div class="title" tagx="title" title="title">
Results and discussion</div> <div class="chemistry" title="sec"><span class="label" tagx="label" title="label">3.1.</span><div class="title" tagx="title" title="title">
Chemistry</div> <p>The synthetic routes used for the construction of target compounds <b>8aâ€"l</b>, <b>9aâ€"k</b>, <b>10aâ€"b</b>, <b>11</b> and <b>12aâ€"d</b> are outlined in <a href="#SCH001">Scheme 1</a>. A series of intermediates (2) was obtained from carbazole (1) via N-alkylation or N-arylation. Next, we performed a formylation reaction (Vilsmayer-Hack) on the intermediates (2) and commercially available compound <b>3</b> in the presence of POCl<sub>3</sub> and DMF to obtain 9-substituted carbazole-3-carbaldehyde analogues <b>4</b> in good yields. Compounds <b>8aâ€"l</b> were prepared by the reaction of each of the series <b>4</b> compounds with metformin hydrochloride in acetic acid. Compounds <b>9aâ€"k</b> were synthesised via the reactions of each of the series <b>4</b> compounds with aminoguanidine hydrochloride in ethanol with a catalytic amount of concentrated hydrochloric acid. Compounds <b>10aâ€"b</b> and <b>11</b> were prepared by reacting compounds <b>4</b> with thiosemicarbazide and semicarbazide, respectively, in the presence of acetic acid in methanol under reflux. Next, we reacted compounds <b>4</b> with isonicotinic in the presence of acetic acid in alcohol to obtain compounds <b>12aâ€"d</b>.</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Scheme 1.</span></a></div>   <p>Synthetic scheme for the synthesis of the target compounds. Reagents and conditions: (a) DMC, DABCO, 95â€‰Â°C, 24â€‰h (<b>2a</b>); KOH, 25â€‰Â°C, 2â€‰h (<b>2b</b>); NaH, DMF, 25â€‰Â°C, 16â€‰h (<b>2câ€"k</b>) (b) POCl<sub>3</sub>, DMF, 90â€‰Â°C, 8â€"18â€‰h (c) AcOH, 120â€‰Â°C, 4â€"8â€‰h (d) CH<sub>2</sub>CH<sub>3</sub>OH, HCl, 40â€‰Â°C, 6â€‰h (<b>9aâ€"k</b>); CH<sub>3</sub>OH, AcOH, 68â€‰Â°C, 4â€‰h (<b>10aâ€"b</b>,<b>11</b>) (e) CH<sub>2</sub>CH<sub>3</sub>OH, AcOH, 70â€‰Â°C, 5â€‰h.</p>   </div> </div> <div class="evaluationofinÂ vitroantimicrobialactivities" title="sec"><span class="label" tagx="label" title="label">3.2.</span><div class="title" tagx="title" title="title">
Evaluation of inÂ vitro antimicrobial activities</div> <p>The antimicrobial activities of the synthesised compounds were then tested against a series of pathogenic bacterial and fungal strains. Several different bacterial strains and one fungal strain were susceptible to most of the compounds tested with MICs in the range of 1â€"64â€‰Âµg/ml. N-aryl carbazole derivatives containing an aminoguanidine or 1,4-dihydro-1,3,5-triazine moiety (<b>8câ€"l</b> and <b>9câ€"k</b>) exhibited potent antibacterial activities with MICs ranging from 0.5 to 16â€‰Âµg/ml. These compounds also exhibited antifungal activity against <i>Candida albicans</i> 7535 with MICs ranging from 1 to 32â€‰Âµg/ml.</p> <p>Compounds <b>8f</b>, <b>8l</b>, <b>9d</b> and <b>9e</b> exhibited strong antibacterial activity against two Gram-positive strains (<i>methicillin-resistant Staphylococcus aureus</i> (MRSA CCARM 3167) and <i>Staphylococcus aureus</i> RN4220) and one Gram-negative strain (<i>Escherichia coli</i> 1924) with MIC values of 0.5 or 1â€‰Âµg/ml. Furthermore, the antibacterial activities of compound <b>8f</b> against Gram-positive bacterial strains (<i>S. aureus</i> RN4220 and <i>Streptococcus mutans</i> 3289) were comparable to the positive control drugs gatifloxacin and moxifloxacin. In addition, compound <b>8f</b> displayed considerable potency against MRSA CCARM 3167 (MIC of 0.5â€‰Î¼g/ml) that was two- and four-fold greater compared with moxifloxacin (MIC of 1â€‰Î¼g/ml) and gatifloxacin (MIC of 2â€‰Î¼g/ml) respectively. In addition, compound <b>8f</b> demonstrated a strong inhibitory activity (MIC of 0.5â€‰Î¼g/ml) against <i>E. coli</i> 1924, which was four-fold greater than the activities of moxifloxacin (MIC of 2â€‰Î¼g/ml) and gatifloxacin (MIC of 2â€‰Î¼g/ml), respectively. In contrast, compound <b>8f</b> showed a weaker activity against the fungus <i>C. albicans</i> 7535 compared with the positive controls.</p> <p>Moreover, we determined the minimum bactericidal concentrations (MBCs) and minimum fungicidal concentrations (MFCs) for compounds whose MIC value less than 256â€‰Âµg/ml against strains. MBCs and MFCs are defined as the lowest bactericidal or fungicidal concentration required to kill a particular bacterial strain or the fungal strain over a fixed incubation time. Most of the series <b>8</b> compounds displayed MBCs at 1â€"2 fold higher than their MICs against the strains tested. Compounds <b>9i</b> and <b>9k</b> also had four-fold higher MIC values compared with their MBCs against <i>S. aureus</i> RN4220 and MRSA CCARM 3167, respectively. The MBC/MIC ratio of compounds <b>9â€‰g</b> and <b>9j</b> were â‰¥4 for <i>S. mutans</i> 3289. Compounds <b>9c</b>, <b>9e</b>, <b>9h</b> and <b>9i</b> demonstrated MFC values that were four-fold higher than their MICs against <i>Candida albicans</i> 7535. Notably, bacteria appeared to be less tolerant to the series <b>8</b> compounds compared with series <b>9</b> compounds. When we altered the phenyl ring substituents of compounds <b>8aâ€"l</b>, we observed a significant effect on the potency of their antimicrobial activities. The order of antibacterial activities were as follows: phenyl group &amp;gt; 2,4-dichloro-substitutions &amp;gt; 4-CH<sub>3</sub>(for compounds bearing an electron-donating group) &amp;gt; halogen substitutionsâ€‰&amp;gt;â€‰benzyl group &amp;gt; 4-CN (for compounds bearing an electron-withdrawing group) &amp;gt; alkyl group. Furthermore, bromo- and chloro-substitutions on the phenyl ring in compounds <b>8aâ€"l</b> were observed to improve their antifungal activity against <i>C. albicans</i> 7535. The antibacterial activity order of compounds <b>9aâ€"k</b> was similar to compounds <b>8aâ€"l</b>. Compounds in series <b>10aâ€"b</b>, <b>11</b> and <b>12aâ€"d</b> generally showed weak activity against all the strains tested in this study, with MICs greater than 256â€‰Âµg/ml. As shown in <a href="#t0001">Table 1</a>, most of the compounds exhibited equivalent or higher potency (with MIC values in the range of 0.5 to 16â€‰Âµg/ml) towards MRSA CCARM 3167 compared with the positive controls gatifloxacin and moxifloxacin (MICs of 2 and 1â€‰Âµg/ml, respectively).</p> <div class="table-wrap_UNKNOWN" id="t0001" orientation="portrait" position="float"><span class="label" tagx="label" title="label">Table 1.</span> <p>Inhibitory activities (MIC/MBC or MFC, Î¼g/mL) of compounds <b>8aâ€"l</b>, <b>9aâ€"k</b>, <b>10aâ€"b</b>, <b>11</b> and <b>12aâ€"d</b> against various bacteria and fungi.</p>  <table frame="hsides" rules="groups"> <colgroup> <col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup>  <thead> <tr> <th rowspan="3" align="left">Compd</th> <th rowspan="2" colspan="3" align="center">R <hr /> </th> <th colspan="3" align="center">Gram-positive strains <hr /> </th> <th align="center">Gram-negative strain</th> <th align="center">Fungus</th> </tr> <tr> <th align="center"><i>S. aureus</i></th> <th align="center">MRSA CCARM</th> <th align="center"><i>S. mutans</i></th> <th align="center"><i>E. coli</i></th> <th align="center"><i>C. albicans</i></th> </tr> <tr> <th align="center">Y</th> <th align="center">R</th> <th align="center">X</th> <th align="center">4220<sup>a</sup></th> <th align="center">3167<sup>b</sup></th> <th align="center">3289<sup>c</sup></th> <th align="center">1924<sup>d</sup></th> <th align="center">7535<sup>e</sup></th> </tr> </thead> <tbody valign="top"> <tr> <td align="left"><b>8a</b></td> <td align="center">H</td> <td align="left">CH<sub>3</sub></td> <td align="center">â€"</td> <td align="center">16/16</td> <td align="center">16/16</td> <td align="center">64/64</td> <td align="center">8/8</td> <td align="center">128/128</td> </tr> <tr> <td align="left"><b>8b</b></td> <td align="center">H</td> <td align="left">C<sub>2</sub>H<sub>5</sub></td> <td align="center">â€"</td> <td align="center">64/64</td> <td align="center">8/8</td> <td align="center">32/128</td> <td align="center">8/16</td> <td align="center">64/128</td> </tr> <tr> <td align="left"><b>8c</b></td> <td align="center">H</td> <td align="left">benzyl</td> <td align="center">â€"</td> <td align="center">4/4</td> <td align="center">0.5/1</td> <td align="center">2/4</td> <td align="center">0.5/1</td> <td align="center">32/32</td> </tr> <tr> <td align="left"><b>8d</b></td> <td align="center">H</td> <td align="left">4-CH<sub>3</sub>C<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>-</td> <td align="center">â€"</td> <td align="center">1/1</td> <td align="center">0.5/0.5</td> <td align="center">2/2</td> <td align="center">0.5/0.5</td> <td align="center">4/8</td> </tr> <tr> <td align="left"><b>8e</b></td> <td align="center">H</td> <td align="left">2-FC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>-</td> <td align="center">â€"</td> <td align="center">4/4</td> <td align="center">0.5/0.5</td> <td align="center">0.5/4</td> <td align="center">0.5/1</td> <td align="center">32/32</td> </tr> <tr> <td align="left"><b>8f</b></td> <td align="center">H</td> <td align="left">2,4-2ClC<sub>6</sub>H<sub>3</sub>CH<sub>2</sub>-</td> <td align="center">â€"</td> <td align="center">0.5/0.5</td> <td align="center">0.5/0.5</td> <td align="center">0.5/1</td> <td align="center">0.5/0.5</td> <td align="center">2/2</td> </tr> <tr> <td align="left"><b>8g</b></td> <td align="center">H</td> <td align="left">2-ClC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>-</td> <td align="center">â€"</td> <td align="center">2/2</td> <td align="center">0.5/1</td> <td align="center">2/4</td> <td align="center">1/1</td> <td align="center">1/1</td> </tr> <tr> <td align="left"><b>8h</b></td> <td align="center">H</td> <td align="left">3-ClC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>-</td> <td align="center">â€"</td> <td align="center">4/4</td> <td align="center">0.5/1</td> <td align="center">2/8</td> <td align="center">1/1</td> <td align="center">2/2</td> </tr> <tr> <td align="left"><b>8i</b></td> <td align="center">H</td> <td align="left">4-ClC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>-</td> <td align="center">â€"</td> <td align="center">2/2</td> <td align="center">0.5/0.5</td> <td align="center">2/2</td> <td align="center">1/1</td> <td align="center">1/1</td> </tr> <tr> <td align="left"><b>8j</b></td> <td align="center">H</td> <td align="left">4-BrC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>-</td> <td align="center">â€"</td> <td align="center">2/2</td> <td align="center">0.5/1</td> <td align="center">2/2</td> <td align="center">1/1</td> <td align="center">2/2</td> </tr> <tr> <td align="left"><b>8k</b></td> <td align="center">H</td> <td align="left">4-CNC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>-</td> <td align="center">â€"</td> <td align="center">16/16</td> <td align="center">16/32</td> <td align="center">16/16</td> <td align="center">8/8</td> <td align="center">8/8</td> </tr> <tr> <td align="left"><b>8l</b></td> <td align="center">Br</td> <td align="left">C<sub>6</sub>H<sub>5</sub>-</td> <td align="center">â€"</td> <td align="center">1/1</td> <td align="center">0.5/0.5</td> <td align="center">1/2</td> <td align="center">0.5/1</td> <td align="center">1/1</td> </tr> <tr> <td align="left"><b>9a</b></td> <td align="center">â€"</td> <td align="left">CH<sub>3</sub></td> <td align="center">NH</td> <td align="center">2/4</td> <td align="center">2/2</td> <td align="center">4/4</td> <td align="center">2/2</td> <td align="center">4/8</td> </tr> <tr> <td align="left"><b>9b</b></td> <td align="center">â€"</td> <td align="left">C<sub>2</sub>H<sub>5</sub></td> <td align="center">NH</td> <td align="center">4/4</td> <td align="center">8/8</td> <td align="center">8/16</td> <td align="center">4/4</td> <td align="center">4/8</td> </tr> <tr> <td align="left"><b>9c</b></td> <td align="center">â€"</td> <td align="left">benzyl</td> <td align="center">NH</td> <td align="center">2/2</td> <td align="center">1/2</td> <td align="center">1/2</td> <td align="center">1/2</td> <td align="center">1/4</td> </tr> <tr> <td align="left"><b>9d</b></td> <td align="center">â€"</td> <td align="left">4-CH<sub>3</sub>C<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>-</td> <td align="center">NH</td> <td align="center">1/2</td> <td align="center">0.5/0.5</td> <td align="center">0.5/1</td> <td align="center">0.5/1</td> <td align="center">1/2</td> </tr> <tr> <td align="left"><b>9e</b></td> <td align="center">â€"</td> <td align="left">2-FC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>-</td> <td align="center">NH</td> <td align="center">2/4</td> <td align="center">0.5/0.5</td> <td align="center">1/1</td> <td align="center">1/1</td> <td align="center">1/4</td> </tr> <tr> <td align="left"><b>9f</b></td> <td align="center">â€"</td> <td align="left">2,4-2ClC<sub>6</sub>H<sub>3</sub>CH<sub>2</sub>-</td> <td align="center">NH</td> <td align="center">2/4</td> <td align="center">1/2</td> <td align="center">2/2</td> <td align="center">2/2</td> <td align="center">16/16</td> </tr> <tr> <td align="left"><b>9g</b></td> <td align="center">â€"</td> <td align="left">2-ClC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>-</td> <td align="center">NH</td> <td align="center">1/2</td> <td align="center">1/1</td> <td align="center">1/4</td> <td align="center">1/1</td> <td align="center">2/4</td> </tr> <tr> <td align="left"><b>9h</b></td> <td align="center">â€"</td> <td align="left">3-ClC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>-</td> <td align="center">NH</td> <td align="center">1/2</td> <td align="center">0.5/0.5</td> <td align="center">1/2</td> <td align="center">2/2</td> <td align="center">2/8</td> </tr> <tr> <td align="left"><b>9i</b></td> <td align="center">â€"</td> <td align="left">4-ClC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>-</td> <td align="center">NH</td> <td align="center">1/4</td> <td align="center">0.5/0.5</td> <td align="center">1/1</td> <td align="center">2/2</td> <td align="center">2/8</td> </tr> <tr> <td align="left"><b>9j</b></td> <td align="center">â€"</td> <td align="left">4-BrC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>-</td> <td align="center">NH</td> <td align="center">2/2</td> <td align="center">0.5/1</td> <td align="center">2/16</td> <td align="center">2/2</td> <td align="center">4/8</td> </tr> <tr> <td align="left"><b>9k</b></td> <td align="center">â€"</td> <td align="left">4-CNC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>-</td> <td align="center">NH</td> <td align="center">2/4</td> <td align="center">2/8</td> <td align="center">2/4</td> <td align="center">2/2</td> <td align="center">2/4</td> </tr> <tr> <td align="left"><b>10a</b></td> <td align="center">â€"</td> <td align="left">CH<sub>3</sub></td> <td align="center">S</td> <td align="center">256/256</td> <td align="center">&amp;gt;256</td> <td align="center">&amp;gt;256</td> <td align="center">&amp;gt;256</td> <td align="center">&amp;gt;256</td> </tr> <tr> <td align="left"><b>10b</b></td> <td align="center">â€"</td> <td align="left">C<sub>2</sub>H<sub>5</sub></td> <td align="center">S</td> <td align="center">&amp;gt;256</td> <td align="center">&amp;gt;256</td> <td align="center">&amp;gt;256</td> <td align="center">&amp;gt;256</td> <td align="center">&amp;gt;256</td> </tr> <tr> <td align="left"><b>11</b></td> <td align="center">â€"</td> <td align="left">C<sub>2</sub>H<sub>5</sub></td> <td align="center">O</td> <td align="center">&amp;gt;256</td> <td align="center">&amp;gt;256</td> <td align="center">&amp;gt;256</td> <td align="center">&amp;gt;256</td> <td align="center">&amp;gt;256</td> </tr> <tr> <td align="left"><b>12a</b></td> <td align="center">â€"</td> <td align="left">benzyl</td> <td align="center">â€"</td> <td align="center">&amp;gt;256</td> <td align="center">&amp;gt;256</td> <td align="center">&amp;gt;256</td> <td align="center">&amp;gt;256</td> <td align="center">&amp;gt;256</td> </tr> <tr> <td align="left"><b>12b</b></td> <td align="center">â€"</td> <td align="left">4-CH<sub>3</sub>C<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>-</td> <td align="center">â€"</td> <td align="center">&amp;gt;256</td> <td align="center">&amp;gt;256</td> <td align="center">&amp;gt;256</td> <td align="center">&amp;gt;256</td> <td align="center">&amp;gt;256</td> </tr> <tr> <td align="left"><b>12c</b></td> <td align="center">â€"</td> <td align="left">2-FC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>-</td> <td align="center">â€"</td> <td align="center">&amp;gt;256</td> <td align="center">&amp;gt;256</td> <td align="center">&amp;gt;256</td> <td align="center">&amp;gt;256</td> <td align="center">&amp;gt;256</td> </tr> <tr> <td align="left"><b>12d</b></td> <td align="center">â€"</td> <td align="left">2,4-2ClC<sub>6</sub>H<sub>3</sub>CH<sub>2</sub>-</td> <td align="center">â€"</td> <td align="center">&amp;gt;256</td> <td align="center">&amp;gt;256</td> <td align="center">&amp;gt;256</td> <td align="center">&amp;gt;256</td> <td align="center">&amp;gt;256</td> </tr> <tr> <td colspan="4">Gatifloxacin</td> <td align="center">0.25/0.25</td> <td align="center">2/2</td> <td align="center">0.25/n.t.<sup>f</sup></td> <td align="center">2/2</td> <td align="center">0.5/0.5</td> </tr> <tr> <td colspan="4">Moxifloxacin</td> <td align="center">0.25/0.25</td> <td align="center">1/2</td> <td align="center">0.25/n.t.</td> <td align="center">2/2</td> <td align="center">0.5/0.5</td> </tr> </tbody> </table> <div class="table-wrap-foot_UNKNOWN"> <div class="fn-type-" title=""> <p>CCARM: Culture Collection Antimicrobial Resistant Microbes; KCTC: Korean Collection for Type Cultures.</p> </div> <div class="fn-type-" title=""> <p><sup>a</sup><i>Staphylococcus aureus RN</i> 4220.</p> </div> <div class="fn-type-" title=""> <p><sup>b</sup><i>Methicillin-resistant S. aureus CCARM</i> 3167.</p> </div> <div class="fn-type-" title=""> <p><sup>c</sup><i>Streptococcus mutans 3289.</i><sup>d</sup><i>Escherichia coli KCTC</i> 1924. <sup>e</sup><i>Candida albicans</i> 7535.</p> </div> <div class="fn-type-" title=""> <p><sup>f</sup>n.t.: Not test.</p> </div> </div> </div> <p>To summarise, our findings revealed that the compounds in series <b>8</b> exhibited significantly higher antimicrobial activities compared with the compounds in the other four series. This suggests that the presence of a dihydrotriazine moiety is critical to the potency of these carbazole derivatives. These results therefore provide further evidence to suggest that aryl groups and the dihydrotriazine moiety play critical roles in the activity of these carbazole compounds.</p> </div> <div class="cellviability" title="sec"><span class="label" tagx="label" title="label">3.3</span><div class="title" tagx="title" title="title">
Cell viability</div> <p>To determine whether the synthesised compounds were selectively toxic towards microbes and not human cells, we evaluated the cytotoxicity of six compounds in two gastric cancer cell lines (SGC-7901 and AGS) and a normal human liver cell line (L-02) using a standard technique. As shown in <a href="#t0002">Table 2</a>, the cytotoxicities of compounds <b>8b</b>, <b>8d</b>, <b>8f</b> and <b>8k</b> were lower than that of compounds <b>9b</b> and <b>9e</b>. Compounds <b>8b</b>, <b>8d</b>, <b>8f</b> and <b>8k</b> had no effect on human liver cell viability at their MICs and, in addition, their IC<sub>50</sub> values were significantly higher than their MIC values. However, the IC<sub>50</sub> values of the series <b>9</b> compounds were close to their MIC values, which make it likely that the promising antibacterial activity of these compounds is due to their cytotoxic properties.</p> <div class="table-wrap_UNKNOWN" id="t0002" orientation="portrait" position="float"><span class="label" tagx="label" title="label">Table 2.</span> <p>Cytotoxic activity (IC<sub>50</sub><sup>a</sup>, Âµg/mL) of compounds <b>8b</b>, <b>8d</b>, <b>8f</b>, <b>8k</b>, <b>9b</b> and <b>9e</b> against human cell lines.</p>  <table frame="hsides" rules="groups"> <colgroup> <col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup>  <thead> <tr> <th rowspan="2" align="left">Compd</th> <th colspan="3" align="center"><i>In vitro</i> cytotoxicity IC<sub>50</sub><sup>a</sup> (Î¼g/mL) <hr /> </th> </tr> <tr> <th align="center">SGC-7901<sup>b</sup></th> <th align="center">AGS<sup>b</sup></th> <th align="center">L-02<sup>c</sup></th> </tr> </thead> <tbody valign="top"> <tr> <td align="left"><b>8b</b></td> <td align="char" char=".">&amp;gt;33.4</td> <td align="char" char=".">&amp;gt;33.4</td> <td align="char" char=".">&amp;gt;33.4</td> </tr> <tr> <td align="left"><b>8d</b></td> <td align="char" char=".">7.1</td> <td align="char" char=".">9.9</td> <td align="char" char=".">10.1</td> </tr> <tr> <td align="left"><b>8f</b></td> <td align="char" char=".">10.0</td> <td align="char" char=".">7.8</td> <td align="char" char=".">9.4</td> </tr> <tr> <td align="left"><b>8k</b></td> <td align="char" char=".">&amp;gt;42.1</td> <td align="char" char=".">&amp;gt;42.1</td> <td align="char" char=".">&amp;gt;42.1</td> </tr> <tr> <td align="left"><b>9b</b></td> <td align="char" char=".">1.8</td> <td align="char" char=".">1.2</td> <td align="char" char=".">3.8</td> </tr> <tr> <td align="left"><b>9e</b></td> <td align="char" char=".">1.5</td> <td align="char" char=".">0.4</td> <td align="char" char=".">1.1</td> </tr> </tbody> </table> <div class="table-wrap-foot_UNKNOWN"> <div class="fn-type-" title=""> <p><sup>a</sup>IC<sub>50</sub> is the concentration required to inhibit the cell growth by 50%. Data represent the average of three independent experiments running in triplicate. Variation was generally between 5 and 10%.</p> </div> <div class="fn-type-" title=""> <p><sup>b</sup>Human gastric cancer cells.</p> </div> <div class="fn-type-" title=""> <p><sup>c</sup>Human normal hepatic cells.</p> </div> </div> </div> <p>Compounds in series <b>8aâ€"l</b>, containing a dihydro-1,3,5-triazine ring moiety, were generally found to have more potent antimicrobial effects but less cytotoxicity compared with the corresponding series <b>9aâ€"l</b> compounds that comprised an aminoguanidine moiety. Interestingly, our results also showed that compound <b>9â€‰b</b> was selectively more toxic to human cancer cells compared with normal human cells. The IC<sub>50</sub> value is about three times higher in normal cells than AGS cell lines. Further studies are required to investigate if this compound has any potential as a new anticancer agent.</p> </div> <div class="dockinganalysis" title="sec"><span class="label" tagx="label" title="label">3.4.</span><div class="title" tagx="title" title="title">
Docking analysis</div> <p>The potent and selective antimicrobial activities of the series <b>8</b> compounds prompted us to study the binding of these derivatives to their potential target, <i>E. coli</i> DHFR. In 3D binding mode, alkyl chains (ethyl and methylene) at the 9-position of carbazole possess considerable flexibility (<a href="#F0002 F0003 F0004">Figures 2â€"4</a>). As shown in <a href="#F0003">Figure 3</a>, the aryl group at the 9-position of carbazole in compound <b>8f</b> inserted deeply into the active pocket of DHFR (composed of Ala7, Trp22, Leu28 and Phe31). Moreover, both the folic acid substrate and compound <b>8f</b> have a nitrogen atom in their heterocyclic rings that forms a hydrogen bond with the <i>E. coli</i> DHFR residue Gly15. The hydrophobic interactions between compound <b>8f</b> and residues in the DHFR active pocket were enhanced due to the presence of the carbazole moiety. In addition, the primary amine group at the N-3 position of the carbazole ring plays an important role in binding to the active site of <i>E. coli</i> DHFR. A salt bridge was formed between the primary amine and Glu17. To summarise, docking results suggested that <b>8f</b>, the compound with the most therapeutic potential, has interacted with the critical active-site residues of <i>E. coli</i> DHFR.</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 2.</span></a></div>   <p>Binding mode of folate inside the <i>E. coli</i> DHFR active site.</p>   </div> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 3.</span></a></div>   <p>Binding mode of <b>8f</b> inside the <i>E. coli</i> DHFR active site.</p>   </div> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 4.</span></a></div>   <p>Binding mode of <b>8b</b> inside the <i>E. coli</i> DHFR active site.</p>   </div> </div> <div class="inhibitionstudiesofcompound8fwithdhfr" title="sec"><span class="label" tagx="label" title="label">3.5.</span><div class="title" tagx="title" title="title">
Inhibition studies of compound 8f with DHFR</div> <p>To investigate whether compound <b>8f</b> can bind to and block the active site of DHFR, we performed <i>inÂ vitro</i> enzyme assays to test the inhibitory effect of compound <b>8f</b> (MIC of 0.5â€‰Î¼g/ml) on DHFR activity (<a href="#F0005">Figure 5</a>). At concentrations of 3 and 10â€‰Î¼mol/L, compound <b>8f</b> decreased DHFR activity by 71% compared with the negative control. The results indicated that compound <b>8f</b> exerts its antibacterial activity via binding to DHFR, which however might not be the only mechanism of action.</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 5.</span></a></div>   <p>Inhibition of DHFR of compound <b>8f</b>.</p>   </div> </div> </div> <div class="conclusions" title="sec"><span class="label" tagx="label" title="label">4.</span><div class="title" tagx="title" title="title">
Conclusions</div> <p>We have designed, synthesised and evaluated the antibacterial and antifungal activities of five series of novel carbazole derivatives. Compound <b>8f</b> showed the most potential as a therapeutic agent, with an MIC of 0.5â€"2â€‰Âµg/ml against selected bacterial strains. Furthermore, compound <b>8f</b> also was the least cytotoxic to SGC-7901, AGS and L-02 cells. Compound <b>9d</b> also exhibited strong antibacterial activity with the cancer therapeutic potential. Therefore, the clinical potential of carbazole derivatives <b>8f</b> and <b>9d</b> could be explored further for future applications in antitumour and antimicrobial therapies.</p> <p>Docking simulation and <i>inÂ vitro</i> enzyme activity assays suggested that binding to DHFR might account for the antimicrobial activity of the compound<b>s</b>. Further studies of the mechanisms of action of these compounds are currently underway in our laboratories and will be reported in due course.</p> </div> </div> <div class="back" title="back"> <div class="COI-statement" title="COI-statement"> <div class="title" tagx="title" title="title">
Disclosure statement</div> <p>We declare that we have no conflict of interest with respect to this study.</p> </div> <div class="references">
References</div> <div tag="ref-list"> <ul> <div class="title" tagx="title" title="title">
References</div> <li tag="ref"><a name="CIT0001" /><span class="label" tagx="label" title="label">1</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="collab'">collab: WHO.</span></span> Antimicrobial resistance. <span class="year" tagx="year" title="year">2018</span> Available from: <a href="http://www.who.int/en/news-room/fact-sheets/detail/antimicrobial-resistance">http://www.who.int/en/news-room/fact-sheets/detail/antimicrobial-resistance</a>.</span></li> <li tag="ref"><a name="CIT0002" /><span class="label" tagx="label" title="label">2</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Paphitou</span><span class="given-names" tagx="given-names" title="given-names">NI.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Antimicrobial resistance: action to combat the rising microbial challenges</span>. <span class="source" tagx="source" title="source">Int J Antimicrob Agents</span><span class="year" tagx="year" title="year">2013</span>;<span class="volume" tagx="volume" title="volume">42</span>:<span class="fpage" tagx="fpage" title="fpage">S25</span>â€"<span class="lpage" tagx="lpage" title="lpage">S8</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23684003">23684003</a></span></span></li> <li tag="ref"><a name="CIT0003" /><span class="label" tagx="label" title="label">3</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="collab'">collab: Infectious Diseases Society of America.</span></span><span class="mixed-article-title" title="mixed-article-title">The 10Ã—â€™20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020</span>. <span class="source" tagx="source" title="source">Clin Infect Dis</span><span class="year" tagx="year" title="year">2010</span>;<span class="volume" tagx="volume" title="volume">50</span>:<span class="fpage" tagx="fpage" title="fpage">1081</span>â€"<span class="lpage" tagx="lpage" title="lpage">3</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20214473">20214473</a></span></span></li> <li tag="ref"><a name="CIT0004" /><span class="label" tagx="label" title="label">4</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Salih</span><span class="given-names" tagx="given-names" title="given-names">N</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Salimon</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yousif</span><span class="given-names" tagx="given-names" title="given-names">E.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis and antimicrobial activities of 9H-carbazole derivatives</span>. <span class="source" tagx="source" title="source">Arab J Chem</span><span class="year" tagx="year" title="year">2016</span>;<span class="volume" tagx="volume" title="volume">9</span>:<span class="fpage" tagx="fpage" title="fpage">S781</span>â€"<span class="lpage" tagx="lpage" title="lpage">S6</span>.</span></li> <li tag="ref"><a name="CIT0005" /><span class="label" tagx="label" title="label">5</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gu</span><span class="given-names" tagx="given-names" title="given-names">W</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hao</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhang</span><span class="given-names" tagx="given-names" title="given-names">G</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis, inÂ vitro antimicrobial and cytotoxic activities of new carbazole derivatives of ursolic acid</span>. <span class="source" tagx="source" title="source">Bioorg Med Chem Lett</span><span class="year" tagx="year" title="year">2015</span>;<span class="volume" tagx="volume" title="volume">25</span>:<span class="fpage" tagx="fpage" title="fpage">554</span>â€"<span class="lpage" tagx="lpage" title="lpage">7</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25537271">25537271</a></span></span></li> <li tag="ref"><a name="CIT0006" /><span class="label" tagx="label" title="label">6</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Indumathi</span><span class="given-names" tagx="given-names" title="given-names">T</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ahamed</span><span class="given-names" tagx="given-names" title="given-names">VSJ</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Moon</span><span class="given-names" tagx="given-names" title="given-names">SS</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">l-Proline anchored multicomponent synthesis of novel pyrido[2,3-a]carbazoles; investigation of inÂ vitro antimicrobial, antioxidant, cytotoxicity and structure activity relationship studies</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2011</span>;<span class="volume" tagx="volume" title="volume">46</span>:<span class="fpage" tagx="fpage" title="fpage">5580</span>â€"<span class="lpage" tagx="lpage" title="lpage">90</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21983331">21983331</a></span></span></li> <li tag="ref"><a name="CIT0007" /><span class="label" tagx="label" title="label">7</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Guillonneau</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Nault</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Raimbaud</span><span class="given-names" tagx="given-names" title="given-names">E</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Cytotoxic and antitumoral properties in a series of new, ring D modified, olivacine analogues</span>. <span class="source" tagx="source" title="source">Bioorg Med Chem</span><span class="year" tagx="year" title="year">2005</span>;<span class="volume" tagx="volume" title="volume">13</span>:<span class="fpage" tagx="fpage" title="fpage">175</span>â€"<span class="lpage" tagx="lpage" title="lpage">84</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15582462">15582462</a></span></span></li> <li tag="ref"><a name="CIT0008" /><span class="label" tagx="label" title="label">8</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Al-Trawneh</span><span class="given-names" tagx="given-names" title="given-names">SA</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zahra</span><span class="given-names" tagx="given-names" title="given-names">JA</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kamal</span><span class="given-names" tagx="given-names" title="given-names">MR</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis and biological evaluation of tetracyclic fluoroquinolones as antibacterial and anticancer agents</span>. <span class="source" tagx="source" title="source">Bioorg Med Chem</span><span class="year" tagx="year" title="year">2010</span>;<span class="volume" tagx="volume" title="volume">18</span>:<span class="fpage" tagx="fpage" title="fpage">5873</span>â€"<span class="lpage" tagx="lpage" title="lpage">84</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20667744">20667744</a></span></span></li> <li tag="ref"><a name="CIT0009" /><span class="label" tagx="label" title="label">9</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhang</span><span class="given-names" tagx="given-names" title="given-names">FF</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gan</span><span class="given-names" tagx="given-names" title="given-names">LL</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhou</span><span class="given-names" tagx="given-names" title="given-names">CH.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis, antibacterial and antifungal activities of some carbazole derivatives</span>. <span class="source" tagx="source" title="source">Bioorg Med Chem Lett</span><span class="year" tagx="year" title="year">2010</span>;<span class="volume" tagx="volume" title="volume">20</span>:<span class="fpage" tagx="fpage" title="fpage">1881</span>â€"<span class="lpage" tagx="lpage" title="lpage">4</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20176480">20176480</a></span></span></li> <li tag="ref"><a name="CIT0010" /><span class="label" tagx="label" title="label">10</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ruan</span><span class="given-names" tagx="given-names" title="given-names">B</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tian</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhou</span><span class="given-names" tagx="given-names" title="given-names">H</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis, crystal structure and inÂ vitro antibacterial activity of two novel silver(I) complexes</span>. <span class="source" tagx="source" title="source">J Organomet Chem</span><span class="year" tagx="year" title="year">2009</span>;<span class="volume" tagx="volume" title="volume">694</span>:<span class="fpage" tagx="fpage" title="fpage">2883</span>â€"<span class="lpage" tagx="lpage" title="lpage">7</span>.</span></li> <li tag="ref"><a name="CIT0011" /><span class="label" tagx="label" title="label">11</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Saturnino</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Palladino</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Napoli</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis and biological evaluation of new N-alkylcarbazole derivatives as STAT3 inhibitors: preliminary study</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2013</span>;<span class="volume" tagx="volume" title="volume">60</span>:<span class="fpage" tagx="fpage" title="fpage">112</span>â€"<span class="lpage" tagx="lpage" title="lpage">9</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23287056">23287056</a></span></span></li> <li tag="ref"><a name="CIT0012" /><span class="label" tagx="label" title="label">12</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bandgar</span><span class="given-names" tagx="given-names" title="given-names">BP</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Adsul</span><span class="given-names" tagx="given-names" title="given-names">LK</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chavan</span><span class="given-names" tagx="given-names" title="given-names">HV</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis, biological evaluation, and docking studies of 3-(substituted)-aryl-5-(9-methyl-3-carbazole)-1H-2-pyrazolines as potent anti-inflammatory and antioxidant agents</span>. <span class="source" tagx="source" title="source">Bioorg Med Chem Lett</span><span class="year" tagx="year" title="year">2012</span>;<span class="volume" tagx="volume" title="volume">22</span>:<span class="fpage" tagx="fpage" title="fpage">5839</span>â€"<span class="lpage" tagx="lpage" title="lpage">44</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22901385">22901385</a></span></span></li> <li tag="ref"><a name="CIT0013" /><span class="label" tagx="label" title="label">13</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hieda</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Anraku</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Choshi</span><span class="given-names" tagx="given-names" title="given-names">T</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Antioxidant effects of the highly-substituted carbazole alkaloids and their related carbazoles</span>. <span class="source" tagx="source" title="source">Bioorg Med Chem Lett</span><span class="year" tagx="year" title="year">2014</span>;<span class="volume" tagx="volume" title="volume">24</span>:<span class="fpage" tagx="fpage" title="fpage">3530</span>â€"<span class="lpage" tagx="lpage" title="lpage">3</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24928405">24928405</a></span></span></li> <li tag="ref"><a name="CIT0014" /><span class="label" tagx="label" title="label">14</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wei</span><span class="given-names" tagx="given-names" title="given-names">ZY</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chi</span><span class="given-names" tagx="given-names" title="given-names">KQ</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yu</span><span class="given-names" tagx="given-names" title="given-names">ZK</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis and biological evaluation of chalcone derivatives containing aminoguanidine or acylhydrazone moieties</span>. <span class="source" tagx="source" title="source">Bioorg Med Chem Lett</span><span class="year" tagx="year" title="year">2016</span>;<span class="volume" tagx="volume" title="volume">26</span>:<span class="fpage" tagx="fpage" title="fpage">5920</span>â€"<span class="lpage" tagx="lpage" title="lpage">5</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27843112">27843112</a></span></span></li> <li tag="ref"><a name="CIT0015" /><span class="label" tagx="label" title="label">15</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhang</span><span class="given-names" tagx="given-names" title="given-names">TY</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Li</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Li</span><span class="given-names" tagx="given-names" title="given-names">YR</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis and antimicrobial evaluation of aminoguanidine and 3-amino-1,2,4-triazole derivatives as potential antibacterial agents</span>. <span class="source" tagx="source" title="source">Lett Drug Des Discov</span><span class="year" tagx="year" title="year">2016</span>;<span class="volume" tagx="volume" title="volume">13</span>:<span class="fpage" tagx="fpage" title="fpage">1063</span>â€"<span class="lpage" tagx="lpage" title="lpage">75</span>.</span></li> <li tag="ref"><a name="CIT0016" /><span class="label" tagx="label" title="label">16</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lebreton</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Newcombe</span><span class="given-names" tagx="given-names" title="given-names">N</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bradley</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Antibacterial single-bead screening</span>. <span class="source" tagx="source" title="source">Tetrahedron</span><span class="year" tagx="year" title="year">2003</span>;<span class="volume" tagx="volume" title="volume">59</span>:<span class="fpage" tagx="fpage" title="fpage">10213</span>â€"<span class="lpage" tagx="lpage" title="lpage">22</span>.</span></li> <li tag="ref"><a name="CIT0017" /><span class="label" tagx="label" title="label">17</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lubbers</span><span class="given-names" tagx="given-names" title="given-names">T</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Angehrn</span><span class="given-names" tagx="given-names" title="given-names">P</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gmunder</span><span class="given-names" tagx="given-names" title="given-names">H</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Design, synthesis, and structure-activity relationship studies of ATP analogues as DNA gyrase inhibitors</span>. <span class="source" tagx="source" title="source">Bioorg Med Chem Lett</span><span class="year" tagx="year" title="year">2000</span>;<span class="volume" tagx="volume" title="volume">10</span>:<span class="fpage" tagx="fpage" title="fpage">821</span>â€"<span class="lpage" tagx="lpage" title="lpage">6</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10782694">10782694</a></span></span></li> <li tag="ref"><a name="CIT0018" /><span class="label" tagx="label" title="label">18</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tsitsa</span><span class="given-names" tagx="given-names" title="given-names">P</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Antoniadou-Vyza</span><span class="given-names" tagx="given-names" title="given-names">E</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hamodrakas</span><span class="given-names" tagx="given-names" title="given-names">SJ</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis, crystal structure and biological properties of a new series of lipophilic s-triazines, dihydrofo-late reduetase inhibitors</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">1993</span>;<span class="volume" tagx="volume" title="volume">28</span>:<span class="fpage" tagx="fpage" title="fpage">149</span>â€"<span class="lpage" tagx="lpage" title="lpage">58</span>.</span></li> <li tag="ref"><a name="CIT0019" /><span class="label" tagx="label" title="label">19</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kumar</span><span class="given-names" tagx="given-names" title="given-names">AA</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mangum</span><span class="given-names" tagx="given-names" title="given-names">JH</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Blankenship</span><span class="given-names" tagx="given-names" title="given-names">DT</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Affinity labeling of chicken liver dihydrofolate reductase by a substituted 4,6-diaminodihydrotriazine bearing a terminal sulfonyl fluoride</span>. <span class="source" tagx="source" title="source">J Biol Chem</span><span class="year" tagx="year" title="year">1981</span>;<span class="volume" tagx="volume" title="volume">256</span>:<span class="fpage" tagx="fpage" title="fpage">8970</span>â€"<span class="lpage" tagx="lpage" title="lpage">6</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7021556">7021556</a></span></span></li> <li tag="ref"><a name="CIT0020" /><span class="label" tagx="label" title="label">20</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Srinivasan</span><span class="given-names" tagx="given-names" title="given-names">B</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tonddast-Navaei</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Skolnick</span><span class="given-names" tagx="given-names" title="given-names">J.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Ligand binding studies, preliminary structure-activity relationship and detailed mechanistic characterization of 1-phenyl-6,6-dimethyl-1,3,5-triazine-2,4-diamine derivatives as inhibitors of <i>Escherichia coli</i> dihydrofolate reductase</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2015</span>;<span class="volume" tagx="volume" title="volume">103</span>:<span class="fpage" tagx="fpage" title="fpage">600</span>â€"<span class="lpage" tagx="lpage" title="lpage">1</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26414808">26414808</a></span></span></li> <li tag="ref"><a name="CIT0021" /><span class="label" tagx="label" title="label">21</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Dell</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lozanov</span><span class="given-names" tagx="given-names" title="given-names">ME</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Shieh</span><span class="given-names" tagx="given-names" title="given-names">WC.</span></span></span> N-alkyation of indole derivatives. <span class="patent" tagx="patent" title="patent">US20040059131</span>, USA; <span class="year" tagx="year" title="year">2004</span>.</span></li> <li tag="ref"><a name="CIT0022" /><span class="label" tagx="label" title="label">22</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Li</span><span class="given-names" tagx="given-names" title="given-names">Z</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Li</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Qin</span><span class="given-names" tagx="given-names" title="given-names">JG.</span></span></span><span class="mixed-article-title" title="mixed-article-title">A simple approach to the synthesis of N-ethylcarbazole</span>. <span class="source" tagx="source" title="source">Huaxue Shiji</span><span class="year" tagx="year" title="year">2001</span>;<span class="volume" tagx="volume" title="volume">23</span>:<span class="fpage" tagx="fpage" title="fpage">297</span>.</span></li> <li tag="ref"><a name="CIT0023" /><span class="label" tagx="label" title="label">23</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kahraman</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Borchardt</span><span class="given-names" tagx="given-names" title="given-names">AJ</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Davis</span><span class="given-names" tagx="given-names" title="given-names">RL</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span> Preparation of carbazole compounds as inhibitors of histamine receptors. <span class="patent" tagx="patent" title="patent">US8080566</span>, USA; <span class="year" tagx="year" title="year">2011</span>.</span></li> <li tag="ref"><a name="CIT0024" /><span class="label" tagx="label" title="label">24</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Li</span><span class="given-names" tagx="given-names" title="given-names">YR</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Li</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Liu</span><span class="given-names" tagx="given-names" title="given-names">JC</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis and biological evaluation of 1,3-diaryl pyrazole derivatives as potential antibacterial and anti-inflammatory agents</span>. <span class="source" tagx="source" title="source">Bioorg Med Chem Lett</span><span class="year" tagx="year" title="year">2015</span>;<span class="volume" tagx="volume" title="volume">25</span>:<span class="fpage" tagx="fpage" title="fpage">5052</span>â€"<span class="lpage" tagx="lpage" title="lpage">7</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26490095">26490095</a></span></span></li> <li tag="ref"><a name="CIT0025" /><span class="label" tagx="label" title="label">25</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhao</span><span class="given-names" tagx="given-names" title="given-names">LM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Guo</span><span class="given-names" tagx="given-names" title="given-names">Z</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Xue</span><span class="given-names" tagx="given-names" title="given-names">YJ</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis and evaluation of 3-substituted-4-(quinoxalin-6-yl) pyrazoles as TGF-type I receptor kinase inhibitors</span>. <span class="source" tagx="source" title="source">Molecules</span><span class="year" tagx="year" title="year">2018</span>;<span class="volume" tagx="volume" title="volume">23</span>:<span class="fpage" tagx="fpage" title="fpage">3369</span>â€"<span class="lpage" tagx="lpage" title="lpage">89</span>.</span></li> </ul> </div> </div>  </body></html>